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ABSTRACT 
 
 
In this study several analytical procedures have been developed 
and optimized to obtain chemical information of diagnostic or 
therapeutic relevance on non-traditional biological fluids, such as 
oral fluid, exhaled breath, and spent dialysate. 
An analytical method to identify warfarin in oral fluid samples by 
HPLC with fluorimetric detection was developed in order to 
investigate the possibility of the minimal invasive monitoring of 
oral anticoagulant therapy. The method was used to highlight the 
presence of the drug in oral fluid with a concentration of 1 - 10 
ng/mL. The results demonstrated the key role played by the 
salivary pH in regulating the drug transfer from the blood. In 
addition, a high correlation (r = 0.84, p = 0.004) between warfarin 
concentration in oral fluid and INR values was found for patients 
with an oral fluid pH ≥ 7.2. 
An analytical methodology based on two-stage thermal desorption 
capillary gas chromatography and mass spectrometry was 
optimized for the analysis of exhaled breath samples. This 
procedure was applied to the non-invasive monitoring in breath 
samples of both volatile compounds during an oral glucose 
tolerance test and sevoflurane anaesthetic and its metabolite 
hexafluoroisopropanol (HFIP) after surgery. A three-compartment 
pharmacokinetic model was developed and fitted to the post-
operative sevoflurane and HFIP breath data. Sevoflurane 
elimination kinetics after surgery were consistent in all subjects 
with a rapid wash-out of sevoflurane within 24 hours, whereas the 
production and elimination of HFIP were more varied. 
Abstract 
 
 
 
2
Photometric and fluorimetric measurements of spent dialysate 
samples were proposed as possible tools to assess the removal of 
uremic toxins with the potential for non-invasive real time 
monitoring of the efficiency of hemodialysis treatment. Excellent 
correlations were obtained between UV absorption at λabs = 292 nm 
and uric acid concentration in spent dialysate (r = 0.90), and 
between uric acid concentration in spent dialysate and in plasma (r 
= 0.92). Furthermore, it was demonstrated that uric acid provides 
the most important contribution to UV absorption at λabs = 292 nm 
in spent dialysate (CUA % = 75 %). A linear model capable of 
predicting concentration values of uric acid in blood from the UV 
absorption data at λabs = 292 nm was developed. 
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INTRODUCTION 
 
 
 Over the last few decades, alternative or non conventional 
matrices such as breath, oral fluid, sweat and other biological 
fluids have become more and more important in diagnostic 
medicine and therapeutic drug monitoring, as well as in toxicology, 
and occupational and environmental exposure. Analysis of these 
alternative fluids provides useful information due to the rapid 
diffusion equilibrium between the dissolved substances in the 
blood capillaries and these fluids through thin membranes. These 
membranes may be biological, such as the alveolar membrane (in 
the case of breath) and the glandular epithelial cell membrane (in 
the case of oral fluid and sweat), or artificial, such as those used in 
hemodialysis treatment. 
In general these types of samples have the advantage that 
collection is almost non-invasive and easy to perform, thus 
minimally affecting the patient. Furthermore, they represent much 
simpler matrices from a chemical point of view, and the analysis 
can be carried out in a shorter time frame and be possibly used in 
outpatient scenarios. These fluids can also provide physiological 
information in real time, which is a useful and can be used 
alongside traditional methods. The main disadvantage of these 
kinds of samples is that compounds of interest are present at very 
low concentrations, and therefore high-sensitivity techniques are 
required to accomplish the analysis. Recent advances in analytical 
techniques have led to the detection of analytes at very low 
concentrations that were unthinkable a few years ago. Currently, 
mass spectrometry, combined with gas or liquid chromatography is 
the most widely used analytical tool because of its high sensitivity 
and specificity, and the ability to handle complex matrices. 
Introduction 
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 The primary goal of this work is to present novel strategies for 
exploiting non-traditional biomarker media such as oral fluid and 
sweat, exhaled breath and hemodialysis fluid for clinical diagnostic 
applications. 
Four specific projects are described to demonstrate the value of 
these biomarker fluids. They are: the monitoring of oral 
anticoagulant therapy in oral fluid, the measurement of diabetes 
biomarkers to assess glucose metabolism, the measurement of 
sevoflurane anesthetic and its primary metabolite 
hexafluoroisopropanol in exhaled breath in order to assess post-
operative liver function, and monitoring the progression and 
effectiveness of hemodialysis. 
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CHAPTER 1 
 
 
Non conventional human fluids 
 
 
1.1 Oral fluid and sweat 
 
Oral fluid in humans is a colourless mouth fluid possessing several 
functions involved in oral health and homeostasis, with an active 
protective role in maintaining oral healthiness [1, 2]. Oral fluid 
helps bolus formation by moistening food, protects the oral mucosa 
against mechanical damage and plays a role in the preliminary 
digestion of food through the presence of α-amylase and other 
enzymes. It also facilitates taste perception, allowing soluble food-
derived molecules to reach the gustative papillae and buffer the 
acid components of food with the bicarbonates (originating from 
salivary gland carbonic anhydrase). Oral fluid also has a role in 
maintaining teeth enamel mineralization: several proteins 
(statherin, proline rich proteins – (PRPs) and mucins) allow Ca++ 
sovrasaturation in oral fluid to be maintained [3]. Oral fluid has 
defence functions against pathogen microorganisms, in the 
presence of defence proteins that react in specific 
(immunoglobulins) or non-specific (lysozyme, peroxydase, 
cystatins, lactoferrin, hystatins and others) ways, inhibiting 
microorganisms growth [4, 5]. 
Sweat is a clear, salty liquid produced by sweat glands in the skin. 
In humans, the main function of sweat is to help regulate body 
temperature by cooling the skin surface. This decrease in 
temperature is caused by the evaporation of water, main 
constituent of sweat at a rate of 0.6 calories per mL of sweat 
Non conventional human fluids 
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evaporated [6]. The amount of sweat secreted from a person in a 
day depends on the needs of thermoregulation itself. Moisture may 
be lost from the skin by either insensible sweat (sweat not visible), 
likely caused by diffusion through the skin, and sensible sweat, 
which is actively excreted during stress and exercise. 
 
1.1.1 Composition and physiology of oral fluid 
secretion 
 
Oral fluid is a complex mix of fluids excreted into the oral cavity 
mainly from three pairs of major salivary glands (parotid, 
sublingual and submandibular) and from a large number of minor 
salivary glands (Figure 1.1). 
 
Figure 1.1 The anatomical positioning of the three pairs of large salivary 
glands; the glandula parotis (1), the glandula submandibularis 
(2) and the glandula sublingualis (3). 
The parotid gland, located opposite the maxillary first molars at the 
top of the mouth, secretes oral fluid derived mainly from blood 
(serous fluid), whereas the sublingual glands, located at the sides 
of the mouth and the submandibular glands, located at the base of 
the tongue excrete both serous fluid and mucin. Minor salivary 
Non conventional human fluids 
 
 
 
7
glands are mainly Von Ebner glands (entirely serous organs 
situated in the connective tissue below the circumvallatae papillae) 
and Blandin-Nühm mucous glands [7]. 
Salivary composition varies in relation to the serous or mucous 
component of the glands [8]; the relative contribution of each type 
of gland to total unstimulated oral fluid secretion varies from 65 %, 
23 %, 8 % to 4 % for submandibular, parotid, Von Ebner and 
sublingual glands respectively [9, 10]. 
Water is the greatest component of oral fluid, representing 99% of 
its composition, and other components such as inorganic 
electrolytes and organic molecules are also present [11]. 
The inorganic part is composed of weak and strong ions including 
Na+, K+, Ca2+, Mg2+, Cl−, HCO3−, HPO32− which can generate buffer 
capacity.The organic part contains components such as body 
secretion products (urea, uric acid and creatinine), putrefaction 
products (putrescine, cadaverine; lipids such as cholesterol and 
fatty acids), and more than 400 types of protein. The most relevant 
proteins have a glandular origin (α-amylase, histatins, cystatins, 
lactoferrins, lysozymes, mucins, and proline-rich proteins (PRPs)) 
or are plasma derived (albumin, secretory immunoglobulin A (sIgA), 
transferrin). The mucin gives oral fluid its sticky character. The low 
protein concentration in oral fluid makes drug binding minimal 
compared to that observed in plasma. 
Oral fluid components have also a non-glandular origin, so oral 
fluid cannot be considered as the only production of salivary 
glands, because it also contains fluids originating from 
oropharingeal mucosae (oral mucosal transudate cells, bacteria, 
fungi, virus, upper airways secretions, gastrointestinal reflux) [12, 
13]. Oral fluid contains also crevicular fluid, an extracellular fluid 
derived from the epithelia of the gingival crevice. Crevicular fluid is 
produced at approximately 2–3 μL/h per tooth and it can be 
considered as a plasma transudate [14]. Oral fluid may also 
Non conventional human fluids 
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contain food debris and blood-derived compounds (actively or 
passively transferred), such as plasmatic proteins, erythrocytes 
and leucocytes in case of oral inflammation or mucosal lesions 
[12]. 
According to Thaysen and his colleagues theory [15], oral fluid 
secretion occurs in two stages: in the first phase a primary oral 
fluid isotonic to blood is released by the acinus cells; in the second 
phase, as this initial fluid moves down the ductal system of the 
salivary gland, an energy-dependent transport process reabsorbs 
sodium and chloride resulting in a hypotonic fluid secretion, with a 
lower ion concentration compared to plasma. In salivary gland 
ducts mineralocorticoid receptors are present, so salivary glands 
are mineralocorticoid-responsive [16]: for this reason salivary K+ 
concentration is higher than the plasma concentration (22 vs 4 
mmol/L) and Na+ concentration is lower in oral fluid compared 
with that in plasma (5 vs 145 mmol/L) [12]. 
Several factors may modify the salivary ionic concentration, 
furthermore, the composition of unstimulated oral fluid is different 
from stimulated oral fluid, which is more similar in composition to 
plasma (Table 1.1). 
Table 1.1 Comparison of inorganic compounds between oral fluid and 
plasma. 
Inorganic 
compounds  
Unstimulated 
oral fluid 
(mmol/L) 
Stimulated 
oral fluid 
(mmol/L) 
Plasma 
(mmol/L) 
Na+ 5 20 - 80 145 
K+ 22 20 4 
Cl- 15 30 - 100 120 
Ca2+ 1 - 4 1 - 4 2.2 
HCO3- 5 15 - 80 25 
Mg2+ 0.2 0.2 1.2 
NH3 6 3 0.05 
Non conventional human fluids 
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For example, an increase in the salivary flow rate, obtained by 
stimulation with acidic food, increases the concentrations of 
sodium, chloride and bicarbonate and decreases the 
concentrations of salivary potassium and phosphate, compared 
with unstimulated oral fluid [17] (Figure 1.2). 
 
Figure 1.2 Relation between the concentration of sodium, potassium, 
chloride and bicarbonate in the oral fluid and the rate of 
salivary flow. 
Healthy adult subjects normally produce 500 – 1500 mL of oral 
fluid per day [11], with typical flows of 0.05 mL/min while sleeping, 
0.5 mL/min while spitting, and 1 mL/min to 3 mL/min or more 
while chewing but several physiological and pathological conditions 
can modify oral fluid production quantitatively and qualitatively, 
e.g., smell and taste stimulation, chewing, psychological and 
hormonal status, drugs, age, hereditary influences, oral hygiene 
[12] and physical exercise [10, 18]. 
Unstimulated oral fluid pH is in the range of 5.6 – 7 and increases 
with stimulation (to more approximate the pH of blood, i.e. 7.4) to a 
maximum of 8.0 [11]. 
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1.1.2 Composition and physiology of sweat secretion 
 
Sweat is a clear, hypotonic solution produced by two types of 
glands: eccrine and apocrine located in epidermis [19]. The 
apocrine glands are larger than the eccrine glands and secrete a 
more viscous substance. The apocrine glands are primarily located 
in the axillae, pubic and mammary areas. Besides opening directly 
onto the skin, sweat glands also develop in close association with 
hair and sometimes open inside hair follicles; as such, sweat is 
thought to be a major contributor to drugs appearing in hair. 
The sweat produced by eccrine glands is a liquid basically colorless 
and odourless, slightly salty, whose composition may vary 
according to different physiological conditions. It consists of a 
dilute (water (99%) is its main constituent) electrolyte solution 
containing high concentrations of sodium, chloride as well as low 
levels of potassium, bicarbonate, glucose, lactic and pyruvic acids 
and urea and ammonium. A substantial individual variability in 
the composition of sweat was found depending on the mode of 
stimulation and age. 
The apocrine sweat, however, is secreted intermittently and 
appears as a viscous liquid, milky, acrid smell, rich in organic 
cellular material, proteins, glycogen and fatty acids. Its pH is 
alkaline due to the presence of ammonia. It is produced in much 
less than the eccrine sweat but, being more easily attacked by 
bacteria, the greater responsibility of the production of body 
odours is attributed to it. 
Sweat acts physiologically by regulating body temperature, since 
its evaporation from the skin surface reduces the excess heat. 
Sweating is increased by nervousness, exercise, stress and nausea 
and decreased by cold. Sweat excretion is also affected by other 
factors, such as ambient temperature, relative humidity, body 
Non conventional human fluids 
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location (in general, sweat glands are distributed over the entire 
body, except for the lips, nipples and external genital organs), 
hormonal imbalances, overactive thyroid gland and the 
sympathetic nervous system, and certain foods and medications. 
Between 300 and 700 mL/day of insensible sweat is produced over 
the whole body, whereas 2–4 L/h of sensible sweat may be 
produced by extensive exercise [11]. 
 
1.1.3 Mechanism of drug transport into oral fluid 
and sweat 
 
Nearly identical considerations are thought to apply to the 
excretion of drugs in sweat as apply to excretion of drugs in oral 
fluid. 
A thin layer of epithelial cells separates the oral fluid ducts from 
the systemic circulation. The lipid membrane of these cells 
determines which molecules may be transferred from the plasma 
into the oral fluid [20]. The clearance of compounds from plasma 
into oral fluid may involve several processes [21]: 
1) ultrafiltration through gap junctions between cells of 
secretory units (intercellular nexus). Only molecules with 
MW<1900 Da are involved (water, ions, hormones such as 
catecholamines and steroids) and their salivary 
concentration is 300–3000 times lower in oral fluid than in 
plasma. 
2) transudation of plasma compounds into oral cavity, from 
crevicular fluid or directly from oral mucosa. The presence in 
the oral fluid of some typical plasmatic molecules, like 
albumin, depends on this mechanism. 
Non conventional human fluids 
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3) selective transport through cellular membranes: by passive 
diffusion of lipophilic molecules (steroid hormones) or by 
active transport through protein channels. 
Salivary substances that so far play the dominant role in clinical 
chemistry diffuse from the blood compartment into oral fluid. At 
least five factors are known which influence the diffusion of the 
drugs into oral fluid [22, 23]: 
1. Molecular mass 
The molecular weight appears to play a minor role, although 
the diffusion coefficient is inversely proportional to the 
molecular radius. As a general rule of thumb that smaller 
molecules diffuse more easily than larger ones. 
2. Lipid solubility 
The major determinant for free diffusibility is the solubility in 
water and/or lipids, especially in the phospholipid layer of 
cell membranes. Lipophilic substances more easily diffuse 
than lipophobic molecules. Abundant evidence has been 
published that the lipophilic character of organic compounds 
as operationally defined by oil/water or octanol/water 
partition coefficients play an important role on drug action at 
all levels of organization (enzyme, membrane and cell) [24, 
25, 26]. 
3. Degree of ionization 
The degree of ionization plays an important role because of 
the partition theory, which states that only the unionized 
fraction is able to pass the lipoid barrier between the three 
compartments: plasma, intracellular space and salivary 
fluid. 
Non conventional human fluids 
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Because the pH value differs between the extra- and 
intracellular space, the total concentration as the sum of the 
ionized and unionized fraction varies on both sides. For 
neutral or weakly acidic drugs with a pKa greater than 8.5 
and weakly basic drugs with a pKa less than 5.5, the 
variability of oral fluid pH has little effect on the oral 
fluid/plasma ratio. For acidic, largely ionized drugs the oral 
fluid/plasma ratio increases with rising pH-value, while for 
basic drugs the reverse situation occurs. In man, oral fluid is 
usually more acidic than plasma. Therefore, the oral 
fluid/plasma ratio is equal to or less than unity for all acidic 
drugs and equal to or greater than unity for all basic drugs. 
If the drug is protein-bound, this statement is only true for 
the free fraction. 
The theoretical oral fluid/plasma ratio can be estimated from 
the equation of Rasmussen (Eq. (1.5 – 1.6)) derived from the 
Henderson–Hasselbalch equation (Eq. (1.1)) and the equation 
for mass balance (Eq. (1.2)), as demonstrated by many 
examples [27, 28, 29]. 
 ݌ܪ ൌ ݌ܭ௔ ൅ log
ሾ஺షሿ
ሾு஺ሿ
 (1.1) 
 ሾܣሿ ൌ ሾܪܣሿ ൅ ሾܣିሿ (1.2) 
where [HA] is the concentration of the non-ionized form of 
the acidic drug, [A-] is the concentration of the anionic form, 
and [A] is the total concentration of drug in both forms. 
Solving both equations for the total amount of drug in either 
form gives: 
 
ሾ஺ሿ
ሾு஺ሿ
ൌ 1 ൅ 10ሺ௣ுି௣௄ೌሻ (1.3) 
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Because Eq. (1.3) applies to both oral fluid and plasma, the 
oral fluid/plasma ratio may be calculated by: 
 
ை௥௔௟ ி௟௨௜ௗ
௉௟௔௦௠௔
ൌ
ൣ஺೚ೝೌ೗ ೑೗ೠ೔೏൧ൣு஺೛೗ೌೞ೘ೌ൧
ൣ஺೛೗ೌೞ೘ೌ൧ൣு஺೚ೝೌ೗ ೑೗ೠ೔೏൧
ൌ ଵାଵ଴
ቀ೛ಹ೚ೝೌ೗ ೑೗ೠ೔೏ష೛಼ೌቁ
ଵାଵ଴ቀ೛ಹ೛೗ೌೞ೘ೌష೛಼ೌቁ
 (1.4) 
A modification must be made to Eq. (1.4) to take into 
account the binding of drugs to plasma and oral fluid 
proteins because only the free neutral drug can cross the 
cellular membranes. Because of protein binding, the 
concentration of drugs in plasma (which drives the diffusion 
process) is reduced. Assuming that the [HA] must be the 
same in both oral fluid and plasma, because of equilibrium 
(HA is the species thought to be responsible for transport 
across the cellular membranes), Eq. (1.4) may be reduced to 
the standard equation, Eq. (1.5). A similar equation (Eq. 
(1.6)) can be derived for basic drugs if it is remembered that 
the un-ionized form of the drug is responsible for the 
transport across the oral fluid–plasma membrane: 
 
ை௥௔௟ ி௟௨௜ௗೌ೎೔೏೔೎ ೏ೝೠ೒
௉௟௔௦௠௔ೌ೎೔೏೔೎ ೏ೝೠ೒ 
ൌ ଵାଵ଴
ቀ೛ಹ೚ೝೌ೗ ೑೗ೠ೔೏ష೛಼ೌቁ
ଵାଵ଴ቀ೛ಹ೛೗ೌೞ೘ೌష೛಼ೌቁ
·
௙೛
௙೚೑
 (1.5) 
 
ை௥௔௟ ி௟௨௜ௗ್ೌೞ೔೎ ೏ೝೠ೒
௉௟௔௦௠௔್ೌೞ೔೎ ೏ೝೠ೒ 
ൌ ଵାଵ଴
ቀ೛ಹೌష೛಼೚ೝೌ೗ ೑೗ೠ೔೏ቁ
ଵାଵ଴ቀ೛಼ೌష೛ಹ೛೗ೌೞ೘ೌቁ
·
௙೛
௙೚೑
 (1.6) 
where fp is the free (unbound) fraction of drug in plasma and 
fof is the free (unbound) fraction of drug in oral fluid. 
The fraction of free drug (not bound to proteins) in oral fluid 
is assumed to be one, because of the much lower 
concentrations of protein in oral fluid compared to plasma. 
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Eqs. (1.5) and (1.6) predict that the concentrations of drugs 
in oral fluid will vary with the free fraction of drug in plasma 
rather than with the total level of drug [30]. 
Since it is only the free form of the drug in plasma that is 
available to produce a pharmacological effect, oral fluid 
concentrations may be of greater therapeutic value than 
plasma levels.   
4. Salivary pH 
On the basis of the above-mentioned partition theory, the 
salivary pH value influences the secretion of ionized drugs. 
The pH-value depends on the flow rate. Stimulation leads to 
an increase of bicarbonate secretion with a concomitant rise 
of the pH-value from 5.8 to 7.8 [11]. Therefore, basic drugs 
are concentrated in oral fluid under resting conditions when 
the salivary pH is below that in blood. On the other hand, 
under maximal stimulation, basic drugs become 
concentrated on the intracellular side of the membrane. 
The salivary pH-value depends on psychological factors; it 
decreases, e. g., under anxiety situations [31]. 
5. Protein binding 
The fraction of a drug bound to protein cannot pass the cell 
membrane. Therefore, the salivary drug concentration 
directly reflects the free plasma fraction of a unionized drug. 
Other factors that can influence the oral fluid/plasma ratio are the 
salivary flow rate, the phenomenon of fluctuating arterial-venous 
differences, the elimination kinetics, and the concentration-
dependent protein binding. 
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1.1.4 Oral fluid and sweat sampling techniques 
 
Oral fluid can be collected under unstimulated (resting) or 
stimulated conditions [32]. Salivary flow can be stimulated by a 
variety of agents: gustatory and masticatory stimuli have been 
used most frequently to increase salivary flow rate. The most 
commonly used stimulants are paraffin wax, Parafilm, rubber 
bands, gum base, and citric acid. 
Common methods of oral fluid collection are spitting, draining, 
suction and collection on various types of absorbent swabs [33]. 
A variety of commercial collection devices that promote easy, quick 
and reproducible collection as well as a cleaner specimen which is 
more suitable for analysis are available [33, 34, 35, 36]. In general, 
these devices consist of an absorbent material that becomes 
saturated in the mouth of the donor, and after removal the oral 
fluid is recovered by centrifugation or by applying pressure to the 
material.  
Examples of commercially available devices include Omni-SAL® 
(Cozart Biosciences Ltd, UK), Salivette® (Sarstedt, Germany), 
Drugwipe® (Securetec, Germany), Quantisal™ (Immunalysis Corp., 
USA), Intercept® (OraSure Technologies, USA), Saliva-Collection-
System® (Greiner-BioOne, USA), ORALscreen™ and Finger 
Collector® (Avitar Technologies, Inc., USA). 
Many sweat collection techniques such as wiping, blotting, 
occlusive patches, iontophoresis with pilocarpine stimulated 
secretions, and the use of capillary tubes have been developed. 
Initially, sweat collection devices consisted of an occlusive bandage 
formed by one to three layers of filter paper or pieces of cotton, 
gauze or towel [37]. Heat or chemicals (e.g. pilocarpine) were used 
to increase sweat production. 
Non conventional human fluids 
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However, this kind of patch was time-consuming to apply, 
uncomfortably large, prone to detachment and yielded a small 
volume of sweat for analysis. 
To overcome these difficulties, non-occlusive sweat collection 
devices have been developed to wear for extended periods of time, 
consisting of an adhesive layer on a thin transparent film of 
surgical dressing to which a rectangular absorbent pad is attached. 
The non-occlusive, semipermeable membrane allows oxygen, 
carbon dioxide, and water vapor to escape. The adsorbent pad 
retains the nonvolatile components of sweat, such as salts, 
proteins, and drugs and metabolites. This device is being marketed 
as the PharmChek sweat patch [38]. A potential problem with the 
PharmChek patch is the absence of a layer between the skin and 
the absorptive pad, to prevent bacterial transfer into the pad and, 
therefore, the possibility of bacterial growth and drug degradation. 
Careful preparation of the skin prior to application of the patch 
should kill or remove bacteria and prevent these problems. 
 
1.1.5 Oral fluid and sweat analysis 
 
Oral fluid and sweat are used mainly in the field of toxicology for 
the detection of drug of abuse using immunochemical and 
chromatographic methods [39, 40, 41]. 
Immunochemical tests, mainly EIA (Enzyme Immuno Assay), are 
used for qualitative analysis of screening to verify the presence or 
absence of substances in the body but not the amount taken or 
still in circulation at the time of the investigation. Such tests 
require small amounts of sample without pre-treatment and have a 
good specificity. 
The screening tests should be subject to confirmation using a 
method that provides structural information on the substances 
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under consideration. In this regard, analytical techniques such as 
mass spectrometry coupled with gas or liquid chromatographic 
separation (GC-MS or LC-MS) are used. 
The quantitative determination by these instrumental techniques 
requires, unlike immunochemical tests, a stage of sample pre-
treatment. Oral fluid and sweat specimens can be treated in a 
similar manner to other biological fluids, by deproteinization, 
ultracentrifugation, using liquid-liquid extraction (LLE) [42, 43, 
44], solid-phase extraction (SPE) [45, 46, 47, 48, 49, 50] and solid-
phase microextraction (SPME) [51, 52] techniques. 
However, because of the simplicity of the matrix, in some cases the 
samples can be analyzed directly by liquid chromatography without 
preparation or following a simple filtration. 
In the recent literature there are many works in which some drugs 
and drugs of abuse (chlorpropamide, propanolol, phenytoin, 
cocaine, amphetamines, cannabinoids and methdone), are 
determined by the analysis of oral fluid or sweat. 
 
1.2 Physiology of respiration 
 
The physiologic purpose of respiration is to carry oxygen from 
ambient air to mitochondria within the cells of peripheral tissues, 
where it is consumed for the oxidation of carbon-containing 
compounds (internal respiration), and to transport carbon dioxide 
away from the cells and the body. The most important mechanism 
for this to happen is diffusion, which is driven by a concentration 
gradient. However, a purely diffusive system can only establish a 
relatively small pressure gradient across the gas exchange barrier 
of the organism. This is acceptable for small organisms (diameter < 
1 mm), however, convection is also needed for larger creatures in 
order to guarantee the high oxygen flow rate needed for their 
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metabolism. In mammals, an air pump consisting of the lungs, the 
airways and the respiratory muscles guarantees that respiratory 
gases are continuously renewed on one side of the alveolar 
membranes, while the heart and the circulatory system accomplish 
the same task on the other side. In this way, a very efficient gas 
exchange system is obtained: diffusion is optimized by having the 
maximum possible gradient across the alveolar capillary 
membranes and across the surface of mitochondria, while a 
minimum oxygen pressure difference exists between blood just 
come out of the lungs and blood reaching the peripheral tissues. 
The availability of a large surface across which gas exchange takes 
place further contributes to the high efficiency of the system. In 
humans, lung surface is so large and so thin that oxygen and 
carbon dioxide transport across the alveolar walls is three-fold 
faster than needed when cardiac output is normal [53]. In most 
cases, the gas-liquid equilibrium between alveolar air and blood 
can be considered almost instantaneous, and the ratio of 
concentrations in pulmonary blood and alveolar air is close to the 
in vitro blood/air partition coefficient. Even so, the O2-carrying 
capacity of the blood would be largely insufficient to meet the 
demand of the systemic tissues if the body had to rely just on 
dissolved oxygen, without a remarkable increase of cardiac output. 
To increase the carrying capacity of the blood, the large majority of 
the oxygen and carbon dioxide is transported bound to proteins or 
in other chemical forms. 
The respiratory system can be divided into two sections (Figure 
1.3): a section, named dead space, which mainly acts as a 
conducting airway (nose, pharynx, larynx, trachea and other 
airways without alveoli), and a section whose main function is gas 
exchange (alveoli and alveolar sacs). 
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The chemical process of gas exchange is diffusion: a substance 
always diffuses from A to B if the concentration or pressure is 
higher in A rather in B. Thus in the alveoli the oxygen pressure 
(100-110 mmHg) is lower than in the inspired air and higher than 
in blood capillaries (40 mmHg). Carbon dioxide pressure in the 
alveoli, on the other hand, is lower (40 mmHg) than in capillary 
blood (46 mmHg) and the CO2 moves in the opposite direction of 
the O2. For the CO2 the difference in pressure is small, but it is 
enough to eliminate the carbon dioxide produced by the organism 
as a result a good diffusivity of this gas. It is also important to 
consider that gas exchanges are also regulated by gas solubility in 
the liquid solution [54]. 
A typical respiratory cycle involves, in a time span of about 5 
seconds, the exchange of half a liter of air in the lungs (tidal 
volume), so that the total ventilation, i.e. the volume of air moved 
in and out of the lungs per unit of time, is about 6 L/min. Not all 
the air we breathe is useful for the renewal of respiratory gases. 
The typical ventilation volume per respiratory cycle of the sections 
is 150 mL and 350 mL, respectively. Before inspiration, dead space 
is filled with end-tidal air remaining from the previous respiratory 
cycle. End-tidal air is the last fraction of expired air, whose 
composition resembles alveolar air. During inspiration, half a litre 
of fresh ambient air is then inhaled into the body, but only the first 
350 mL reach the alveoli together with 150 mL of end-tidal air 
contained in the dead space, where they are diluted and mixed 
with alveolar air. During expiration, 150 mL of fresh ambient air, 
which filled the dead space, and 350 mL of air coming from the 
alveolar region are exhaled through the nose and/or mouth in 
sequence. By analyzing a respiration cycle, it can be noted that 
dead space is alternately filled with ambient and end-tidal air, and 
that only 350 mL of ambient air actually ventilates the lungs. Since 
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the volume of air contained in the lungs during normal breathing is 
approximately 3 L, it follows that the composition of alveolar air is 
pretty stable during respiration (the cyclic variations of oxygen and 
carbon dioxide are about 2% and 5%, respectively). 
During expiration the breath composition changes in order to 
empty the airways and the lungs. Such a process can be monitored 
by tracking the CO2 content in breath, Figure 1.5 [55]. 
 
Figure 1.5  CO2 breath profile during a single respiratory cycle. 
Three phases can be identified: during Phase I the air in dead 
space is eliminated and the composition of this fraction is low in 
CO2, being similar to inspired air; during Phase II, when mixed 
dead volume and alveolar air are emitted, the partial pressure of 
CO2 quickly increases until a maximum value (35 mmHg) is 
reached and then during Phase III a plateau level that 
asymptotically approaches the alveolar concentration is reached; 
only in Phase III is the alveolar air eliminated, containing the 
volatile compounds released from blood. 
Ambient air is the main source of xenobiotic contaminants and 
oxygen. Its content of oxygen and carbon dioxide is fairly constant, 
while the concentrations of xenobiotics may be highly variable. 
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Dead space air has a composition close to ambient air (but a higher 
water content). Differences may arise due to the chemicals 
originating and/or released in the conducting airways or to gas 
exchanges with the mucus layer (mainly for water soluble 
compounds). 
The composition of alveolar air is due to the interaction of ambient 
air with blood through the alveolar membrane. There are 
considerable non-homogeneities in the composition of alveolar air 
in different lung regions even in healthy subjects, since posture 
and gravity alter both local ventilation (exchange of the air in the 
lungs) and perfusion (blood circulation). Pulmonary ventilation and 
perfusion are mainly regulated by respiratory and cardiac 
frequency [55, 56]. 
When the composition of ambient air changes, the time needed for 
each breath fraction to reach a new equilibrium ranges from a few 
seconds for dead space air to minutes or hours for alveolar air. 
In fact, after exogenous compounds have reached pulmonary 
alveoli dissolved in blood on the basis of their blood/air partition 
coefficients, the compounds are then transferred through the body 
and released in the different tissues depend on the chemical 
affinity. The concentration of each compound in alveolar air is the 
result of a dynamic equilibrium that involves several 
compartments, each with its specific time constant. 
In most cases, blood is the main source of markers and for this 
reason alveolar air should be considered the most representative of 
an individual’s condition. If markers are released from conducting 
airways, dead space air should be sampled. 
 
Non conventional human fluids 
 
 
 
24
1.2.1 Breath sampling techniques 
 
The inter- and intra-individual variability of physiology, the 
presence of circadian rhythms in the production and emission of 
some compounds, and the existence of confounding factors due to 
food consumption or ambient air make the collection of 
representative samples particularly difficult in many cases. There 
are no general rules to follow and this lack of standardization in 
the sampling procedures has been proposed as a possible 
explanation for the contradictory results obtained by different 
authors along with the intrinsic difficulties of accurate and precise 
quantitative analysis of gas sample [57]. 
Exhaled air can be sampled in two ways, i.e., by mixed expiratory 
sampling and end-tidal sampling, respectively. Mixed expiratory 
sampling entails collecting total breath, including the air contained 
in the upper airways (dead space) which experiences no gas 
exchange with blood. End-tidal sampling involves the collection of 
only end-tidal air, which contains most of the chemical information 
on blood composition. Separate sampling during expiration of dead 
volume air and end-tidal air may be advantageous in breath 
research in terms of providing an insight into the origin of 
chemicals identified in breath samples. The presence of exogenous 
compounds in breath is one of the main sources of noise affecting 
breath analysis; how to discriminate between compounds with 
endogenous (i.e., produced inside the body by the physiological or 
pathological metabolism) or exogenous origin is an age-old 
question. The debate on the best solution to this problem still 
divides the scientific community. Some authors propose that each 
compound should be weighed on the basis of its concentration 
gradient between breath and ambient air [58], while others suggest 
that compounds whose concentration in ambient air is comparable 
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with or higher than that in breath should not be taken into 
account in the characterization of subjects [59] and finally there 
are those who provide the subjects with purified air in order to 
circumvent the problem [60, 61]. 
Several types of breath sampling devices have been reported in the 
literature or are commercially available. Most are simple 
combinations of valves and tubing which the study subject uses to 
fill a sampling bag or a syringe [62, 63, 64], or a pre-evacuated 
stainless steel canister [65, 66 67]. In all these cases, the subject is 
breathing ambient air, thus the mixed expiratory sampling is 
accomplished. 
In the latter case, the subjects themselves control the sampling by 
opening a manual valve through which their breath is sucked into 
the canister. The canisters afford optimum stability of the sample 
and absorption on the canister walls for specific class of 
compounds can be minimized by a suitable treatment of the 
surfaces. Nevertheless, they are relatively heavy and bulky if a 
large number of samples have to be collected. Due to cost, they are 
not disposable and so an effective cleaning procedure is needed 
[68, 69, 70]. The use of plastic bags has been investigated by many 
authors as a possible alternative [71, 72, 73]. The stability of 
samples can be affected by the absorption on, or permeation 
through the bag walls, the possible contamination due to the 
release of bag materials, and the cleaning procedures in the case of 
multiple use. Tedlar and Nalophan bags are largely used thanks to 
low cost and handiness. 
Other authors have suggested more complex devices to deliver 
purified air to their subjects [74, 75]. Two passive devices are 
commercially available that allow the sampling of end-tidal air. The 
first sampler, QuinTron, is produced by Campro Scientific GmbH 
(Germany) and consists of a tee-shaped connector housing two 
one-way valves in its two outlets. The core of each valve is a thin 
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silicon disc that seals the outlet until threshold pressure is 
exerted. The two valves are regulated to open at different 
pressures; a 250 mL bag is connected to the valve opening at the 
lower pressure, while a 750 mL bag is connected to the other valve. 
A mouthpiece is fitted to the inlet of the tee-shaped connector. 
When the subject blows air into the device, the pressure rises in 
the connector until the first valve opens and the corresponding bag 
is filled with dead space air. The pressure then starts increasing 
again until the second valve opens, allowing the remaining breath 
to be released into the other bag. Another sampler, BioVOC™, is 
produced by Markes International (UK). The subject is asked to 
blow through a mouthpiece into a cylinder with an open end. Only 
the last portion of end-tidal air (150 mL) remains in the cylinder 
after expiration. The mouthpiece is then replaced with a piston 
used to push the sample through an absorbing tube which has 
been connected to the previously open end of the cylinder. 
Although these systems do not provide the optimum solution, they 
are attractive for their simplicity and low cost. Their main 
limitations are the poor control of the sampling conditions and the 
limited volume that can be sampled in a single breath. A more 
sophisticated Breath Collecting Apparatus (BCA) was developed by 
Phillips and produced by Menssana Research [58]. In this system, 
the subject breathes through a mouthpiece assembly consisting of 
an inlet valve for the inspiration of ambient air and an outlet valve 
connected to an open-ended stainless steel cylindrical reservoir, 
which is thermostated at 40 °C to avoid the condensation of water. 
The sampling port, located at the end of the reservoir near the 
mouthpiece, is connected in sequence to an absorption tube, a flow 
meter and a computer-controlled pump. The end-tidal air sampling 
is accomplished by activating the pump at appropriate times after 
expiration, since no measurements of expiratory gas concentration 
and flow are taken. The total volume sampled in the absorbing 
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tube during multiple breaths can be selected by the user. A CO2-
controlled breath sampling device was proposed by Schubert et al 
for mechanically ventilated patients [76]. A fast responding infrared 
absorption mainstream CO2 analyzer supplies data to an electronic 
processing unit, which actuates a two-way valve diverting breath 
flow to an absorbing trap when the percentage volume of carbon 
dioxide exceeds the set-up point. 
Alternatively, the breath sample can be collected into a bag and 
then pre-concentrated off-line into an absorption tube [77]. The 
system enabled the sampling of large volumes on multiple breaths 
and the separation of breath fractions by real time monitoring of 
CO2 concentration. 
Loccioni humancare with Professor T. Risby had developed novel 
sampling devices: 
1)  Single Breath Sampler developed to characterize a single 
breathing act. Mouth pressure and carbon dioxide 
concentration in real time are displayed and allow the 
breathing subject to apply a biofeedback technique on 
pressure and stabilize the expiration flow to a standard value 
making sampling repeatable and reliable.  It is designed for 
connection with real time monitors (mass spectrometry, 
tunable diode laser analysers, photo-acoustic laser 
spectrometers, etc.) allowing to capture the signal from an 
external sensor for easy and fast data collection. 
2)  Multiple Breath Sampler developed to allow the subject 
breathing in a regular way and sample multiple breathing 
acts. Parameters can be set and changed to select the 
portion of interest in breath, according to the study 
performed. Breath can be then sample in desorption tubes or 
bags and analyzed with standard methods. It is designed for 
off-line gas analysis (gas cromatography, mass spectrometry, 
etc.). 
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1.2.2 Analytical techniques used for chemical breath 
characterization 
 
Several techniques have been applied to breath analysis that can 
be differentiated with respect to detection power, types of analyte to 
which they can be applied, capability of providing unambiguous 
identification, or possibility of providing real-time data [78, 79]. 
The high separation efficiency of capillary gas chromatography (GC) 
and the high identification capability of mass spectrometry (MS) 
make GC-MS the most common method used to measure low 
concentrations of more than one thousand VOCs present in human 
breath [80, 81]. 
Due to the extremely low level of most substances in exhaled 
breath, a pre-concentration step is required in most cases to 
enhance detection power. Generally, there are three approaches to 
achieve pre-concentration, namely, the chemical, cryogenic, and 
adsorptive approach [82, 83, 84, 85]. 
The adsorptive trapping is currently the most convenient and 
widely used method. It retains volatile compounds by binding them 
to specific sorbents. There are two types of pre-concentration 
techniques that use solid phase adsorption, i.e., Solid Phase Micro-
Extraction (SPME) and Solid Phase Extraction (SPE). 
The SPME technique, developed by Pawliszyn in 1989, combines in 
one step analyte collection and extraction [86]. The SPME [87] does 
not use any solvent and may be easily coupled with the most 
diffused chromatographic techniques. This method utilizes a fused 
silica fiber (typical diameter, 50-200 µm) coated with a thin layer of 
stationary phase (typical thickness 10-100 µm) mounted in a 
holder. During extraction, the fibre is exposed to the sample for a 
pre-established time during which the analytes reach the 
distribution equilibrium between the sample and the fiber coating. 
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The extraction efficiency depends on the value of the analyte 
partition coefficient and the mass ratio between the sample and the 
stationary phase. Afterwards, the fiber is withdrawn in the holder 
which in turn is inserted, for a pre-established time, in a modified 
split/splitless injector of the GC with a small diameter liner (0.75 
mm ID) heated at a suitable temperature so that the analytes are 
thermally desorbed and transferred into the column by the carrier 
gas [88]. The optimum time and temperature of desorption and the 
carrier gas flow influence recovery have to be found experimentally. 
Several types of coatings with different thicknesses and polarities 
are commercially available and have an affinity with different 
classes of compounds [89, 90]. This extraction technique does not 
require any particular pre-treatment and is fast and easy use. The 
main disadvantages of this technique are the low pre-concentration 
factor, due to the limited capacity, and the difficulty in performing 
quantitative analysis, especially at trace level, due to the 
competition for absorption sites among minor constituents and 
more abundant compounds [91, 92]. 
In the SPE technique, a known volume of the sample passes 
through a desorption tube, packed with a suitable stationary 
phase, and the analytes are then retained on the basis of their 
chemical-physical properties. Analytes are released from the 
sorbent by applying a sharp temperature increase (Thermal 
Desorption (TD)) and transferred to the chromatographic column 
using a flow of an inert gas. Broadening of the chromatographic 
signal may happen and can be reduced by a two stage desorption 
system. In fact, the analytes desorbed from the tube are focused in 
a cryogenic capillary trap, which has a reduced internal volume. 
The trap is then rapidly heated. In this case the desorption process 
is faster and the transfer to the chromatographic column is 
performed with a smaller volume of carrier gas. 
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In order to have better analyte recovery and more reproducible 
results the packing material, desorption temperatures, timing, and 
gas flows need to be optimized both for the desorption tube and the 
focusing trap [93]. Sorbents should have high value of 
Breakthrough Volume (BTV), low affinity for water, and high 
thermal stability [92]. Carbon-based materials such as Carbon 
Molecular Sieves (CMS) and Carbon Blacks (CB) are frequently 
used, although they present some drawbacks [94]. Graphitized 
Carbon Black (GCB) is a very hydrophobic adsorbent with excellent 
thermal stability, low affinity to water, and high affinity to very 
volatile compounds [95]. Therefore, GCB could be used for the 
sampling of VOCs in exhaled breath, which has a high humidity 
content, without additional treatment. 
Many of the porous organic polymers derive from the stationary 
phase used in a packed GC column. Tenax is one of the most 
frequently used trapping materials. This polymer is hydrophobic 
and does not retain water. Due to its low surface area (30 m2/g), 
very volatile compounds are not trapped. The co-precipitated GCB 
with Tenax was introduced on the market as a Tenax GR which 
combines advantages of both materials [96]. If the sample contains 
compounds with different chemical-physical properties, the use of 
a multi-bed tube should be preferred. 
Information on breath composition can also be obtained from 
direct breath measurements performed by different mass 
spectrometric techniques: Selected Ion Flow Tube Mass 
Spectrometry (SIFT-MS) or Proton Transfer Reaction Mass 
Spectrometry (PTR-MS). These techniques enable to eliminate the 
collection and pre-concentration phases and give real time 
responses. 
SIFT-MS is a technique originally developed for the determination 
of rate coefficients for gas phase reactions. Recently SIFT has been 
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applied to the detection of trace gases in air and breath [97, 98, 
99]. 
In short, the analysis occurs through a process of chemical 
ionization in a reaction tube (or flow tube). To analyze VOCs, a 
sample is introduced into the flow tube at a precisely controlled 
rate. Inside the flow tube, precursor ions, usually H3O+, NO+, or 
O2+, react with VOCs present in the sample. This reaction results 
in the formation of product ions, which are analyzed by a 
quadrupole mass spectrometer to identify and quantify VOCs. 
SIFT-MS has been used for the monitoring of ammonia, acetone, 
isoprene, and ethanol in breath of healthy volunteers [100, 101], 
for the investigation of ethanol metabolism [102], the control of 
ovulatory cycle [103], the analysis of smokers’ and passive 
smokers’ breath [104], the assessment of exposure to volatile 
solvents [105], and the detection of bacterial infections, renal 
failure and diabetes [99]. 
PTR-MS is a relatively new technique allowing the quantification of 
gaseous VOCs at low concentration in real time [106]. This 
technique is different from SIFT due to some expedients adopted to 
increase detection power.  The system works with an empty 
cathode ion source, which produces a high density of primary ions 
travelling across the tube without a pre-selector.  The sample is 
introduced inside the tube without a carrier gas, thus avoiding 
dilution and increasing detection power by two orders of magnitude 
compared to SIFT [107]. 
In brief, chemical ionization is applied based on proton-transfer 
reactions, with H3O+ as the primary reactant ion, which is most 
suitable when air samples containing a wide variety of trace volatile 
organic compounds are to be analyzed. Almost all VOCs have 
proton affinities larger than H2O, and therefore proton transfer 
occurs on every collision (H3O+ + VOC → VOCH+ + H2O). The 
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ionized VOCs by proton transfer from H3O+ are analyzed in mass 
types rather than concentration. 
PTR-MS has been used for exhaled breath profiling [108] and real 
time monitoring of anaesthetic agents [109] and to study effects of 
hemodialysis [110] or smoking [111]. 
In recent years Ion Mobility Spectrometry (IMS) has developed in 
comparatively small and effective devices to determine trace 
quantities of VOCs down to the low ppbv range in air [112, 113, 
114]. The fundamental principle of operation is to separate ions 
according to their gas phase mobility as they travel through a 
purified gas in an electric field at atmospheric pressure. 
The major advantage of IMS is that no vacuum systems are 
required and the ambient air can be used as carrier gas. IMS is 
often coupled with a GC system because of the intrinsic limited 
detection power, especially in the case of the detection of complex 
mixtures [115]. IMS has been used to identify some metabolites 
[116] as well as bacteria in human breath [112] coupled with 
multi-dimension capillary GC. 
Recent advances in laser spectroscopic techniques make it possible 
for breath analysis to be performed on-line without the need to 
collect breath in containers or traps, thus allowing information 
about concentration during different phases of exhalation to be 
obtained. Laser-assisted analytical measurements are specific, fast, 
and characterized by a great detection power, and trace gas at the 
picomolar level can be determined with sub-sec resolution [117, 
118, 119]. The major laser spectroscopic techniques, which are 
characterized by their high sensitivities and are currently being 
applied at breath analysis for detection of CO, CO2, NH3, NO, C2H6, 
C2H4 and COS, include tunable diode laser absorption 
spectroscopy (TDLAS), cavity ring-down spectroscopy (CRDS), 
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cavity leak-out absorption spectroscopy (CALOS), photo-acoustic 
spectroscopy (PAS) [120, 121, 122, 123]. 
Breath analysis is also conducted by using electrical sensors, 
which are comparatively inexpensive and smaller in size, but they 
have low detection selectivity and require frequent calibrations 
[124, 125, 126]. 
 
1.3 Renal physiology 
 
The urinary system consists of two kidneys that filter blood and 
deliver the produced urine into the two ureters. From the ureters 
the urine is passed to the urinary bladder, which is drained via the 
urethra during urination. The kidneys  are bean-shaped organs of 
about 11 cm long, 4 to 5 cm wide and 2 to 3 cm thick, and lie 
bilaterally in the retroperitoneum in the abdominal cavity. 
 
Figure 1.6 Internal anatomy of the kidneys. 
The smallest functional unit of the kidney is the uriniferous tubule, 
each containing a nephron and a collecting tubule. There are 
approximately 1 to 1.3 million nephrons in each kidney. One 
nephron is composed of a vascular part (glomerulus), a drainage 
part (Bowman's capsule), a proximal tubule, Henle’s loop and a 
distal tubule (Figure 1.6). Several nephrons are drained by one 
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collecting tubule, which enlarges downstream until it becomes a 
duct of Bellini and perforates the renal papilla. 
The major function of the kidneys is removing toxic by-products of 
the metabolism and other molecules smaller than 69000 Da (i.e. 
smaller than albumin) by filtration of the blood flowing through the 
glomerulus. They also regulate body fluid composition and volume. 
Specifically resorption of salts (Na+, K+, Cl-), glucose, creatine, 
proteins, and water takes place in the tubular parts. Because of 
these eliminating and conserving functions, the kidneys also 
contribute to the regulation of the blood pressure, hemodynamics, 
and the acid-base balance of the body. Additionally, kidneys have 
an endocrine function: they produce the hormone renin, 
erythropoietin and prostaglandines (derivatives of essential fatty 
acids to maintain homeostasis) and help in converting vitamin D to 
dihydroxycholecalciferol, a substance which controls calcium 
transport [53]. 
Renal insufficiency is a condition in which the kidneys lose their 
ability to purify the blood leading to the accumulation of toxins and 
waste products. According to the duration in which this occurs 
renal insufficiency can be divided into two main categories: acute 
(days to months) and chronic (years) renal failure. 
As renal failure progresses, glomerular filtration rate as well as the 
amount of nephrons decreases. The main causes of end stage renal 
disease are diabetes and hypertension. 
Dialysis is an artificial modality of renal replacement therapy used 
to manage renal insufficiency. It removes excess liquids and 
uremic toxins, assures the fluid balance and acid-base 
equilibrium, but partially replaces kidney functions: it can only 
replace a part of the excretory function, whereas the endocrine and 
metabolic function of the kidney cannot be restored. 
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The invention of dialysis dates back to the 19th century, when 
Thomas Graham discovered a method for separating gases by 
diffusion [127]. However, hemodialysis was not widely available till 
1960, when the first patient was treated for chronic renal failure by 
intermittent hemodialysis. 
 
1.3.1 Fundamentals of hemodialysis 
 
Insufficient kidney function can lead to the accumulation of excess 
electrolytes, waste products and fluid. The concentrations of these 
compounds can reach toxic levels and need to be removed from the 
blood stream. Hemodialysis is a blood purifying therapy in which 
the blood of a patient is circulated through an artificial kidney, also 
called hemodialyzer. This is realized in an extracorporeal circuit 
(Figure 1.7) where one or two needles (or catheters) can be used as 
the patient’s vascular access. A general hemodialysis therapy lasts 
about 9-15 hours a week, mostly spread over three sessions. 
 
Figure 1.7 The extracorporeal circuit in hemodialysis. 
Two types of hemodialyzers are in use: plate and hollow fiber 
dialyzers [128]. In a plate dialyzer, membrane sheets are packed 
together and blood and dialysate flow in subsequent layers. The 
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hollow fiber dialyzer consists of thousands of small capillaries 
(inner diameter in the range of 200 μm and wall thickness of 8-40 
μm). Blood flows inside the capillaries whereas dialysate flows 
counter currently around them. Typical blood flow rates are in the 
range of 200 up to 350 mL/min, while dialysate flows are 
preferably twice the blood flow with a typical value of 500 mL/min. 
Membranes used in hemodialysis are of two basic types: organic 
cellulose derivatives (i.e. cuprophan, cellulose di-, tri- acetate and 
hemophan) and synthetic membranes (i.e. polyacrylonitrile, 
polysulfone, polyamide, polymethyl-methacrylate). With respect to 
the membrane characteristics, distinction can be made between 
low, medium, and high flux dialyzers on one hand (ultrafiltration 
coefficient lower than 15, between 15 and 40, and higher than 40 
mL/h/mmHg, respectively), and low and high area dialyzers on the 
other (membrane surface lower and higher than 1.5 m², 
respectively). 
In hemodialysis therapy, the dialyzer succeeds in purifying the 
blood and extracting the excess water due to basic transport 
phenomena, such as diffusion, ultrafiltration, and osmosis. As 
transport takes place between the blood and dialysate 
compartment over a semi-permeable membrane, fluid 
characteristics and membrane properties should also be 
considered. 
Molecules in the blood, with a molecular size smaller than the pore 
size of the membrane, can diffuse across the semi-permeable 
membrane into the dialysate. The driving force for the diffusion is 
the concentration difference between the blood (high concentration) 
and the dialysate (low concentration). The diffusion is governed by 
Fick’s law according to: 
 ܬ ൌ െܦ · ܣ · ௗ௖
ௗ௫
ൌ െܦ · ܣ · ∆௖
∆௫
 (1.7) 
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where J is the flux [mmol·L-1], D is the diffusity [cm2·s-1], A is the 
area of the membrane [m2], and dc/dx is the concentration 
gradient [129]. 
The diffusity D is a unique property of the solute-solvent system at 
a specific temperature. The sign convention is adopted, which 
states that diffusion occurs in positive direction, i.e. from the 
region of higher activity (conc.) to that of lower so that the 
concentration will be decreasing in the direction of flux. Therefore, 
the right hand side of equation 1.7 must carry a negative sign 
[129]. The diffusity D is a constant at any particular temperature. 
Therefore, equation 1.7 can be written as: 
 ܬ ൌ െܭ଴ · ܣ · ∆ܥ (1.8) 
where K0 is the mass transfer coefficient [cm·min-1] and ∆C is the 
concentration difference [mmol·L-1] [129]. 
Equation 1.8 states that with a specific dialyzer (K0·A is constant), 
the transfer of solutes from blood into dialysate will depend directly 
on the concentration difference (∆C). This concentration difference 
is the driving force of dialysis. The concentration of solutes in blood 
and dialysate will linearly change, when solutes are transferred 
from one to the other. The solute concentration in blood decreases 
whilst in the dialyzer (cBi → cBo). In contrast, the concentration in 
the dialysate increases (cDi → cDo). The concentration difference at 
any point in the dialyzer determines the flux. 
On the other hand, excessive body fluid has also to be removed 
from the body. However, the driving force for the removal of 
excessive body fluid is not same as for the solute removal (∆C). The 
transfer of water from the patient to the dialysate is determined by 
a pressure difference (∆P). The water flux can be calculated as 
follows: 
 ܳி ൌ ܭ௎ி · ሺ ஻ܲ െ ஽ܲሻ (1.9) 
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where QF is the ultrafiltration rate [ml·min-1], and PB-PD is the 
pressure difference (driving force) between the pressure on the 
blood side and the dialysate side [129]. 
 
1.3.2 Dialysis fluid characteristics 
 
The hemodialysis fluid should be considered as a temporary 
extension of the patient's extracellular fluid because of the bi-
directional transport process when blood and dialysate are flowing 
through the dialyzer. Therefore, the composition of dialysis fluid is 
critical in achieving the desired blood purification and body fluid 
and electrolyte homeostasis. It contains (Table 1.2) reverse osmosis 
water, dextrose and different electrolytes like calcium-, 
magnesium-, potassium- and sodium chloride and sodium acetate 
or –bicarbonate [130]. The latter two fulfill the function of dialysate 
buffer, responsible for the correction of metabolic acidosis in the 
uremic patient. Hydrogen ions (H+) are, soon after their production, 
buffered by plasma bicarbonate, and can only be removed by the 
diffusive flux of alkaline from the dialysate into the blood replacing 
the blood buffers [131]. 
Table 1.2 Usual composition of dialysis fluid. 
Compound  Concentration (mmol/L) 
Sodium 132 - 155 
Potassium 0 - 4 
Calcium 1.25 – 2 
Magnesium 0.25 – 0.75 
Chloride 90 - 120 
Bicarbonate 27 - 40 
Dextrose 0 – 5.5 
pH 7.1 – 7.3 
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Besides the chemical composition, the physical and microbiological 
characteristics are also important. As the use of highly permeable 
membranes in hemodialysis is responsible for backfiltration and/or 
backdiffusion (filtration and/or diffusion from the dialysate 
compartment towards the blood compartment), toxic and pyrogenic 
substances can move from the dialysate towards the blood 
resulting in febrile reactions [132]. 
Nowadays, the composition of dialysis fluid is prescribed for each 
single patient to individualize the dialysis therapy according to the 
personal needs. The actual dialysis machines guarantee accurate 
proportioning of treated water and concentrated salts, continuous 
monitoring of the final composition and a constant maintenance of 
the required conductivity values. 
The hemodialysis system is the end point of a hydraulic circuit 
where tap water is changed into reverse osmosis water through 
water supply, water pre-treatment, water purification [133], and 
dialysis fluid preparation. The pre-treatment consists of flowing tap 
water through filters, softener, carbon filter and microfilters. The 
subsequent treatment concerns flow through one or two reverse 
osmosis membranes and a deionizer, closing the purification chain 
with ultrafiltration and submicrofiltration. 
 
1.3.3 Uremic toxins 
 
The uremic syndrome results from the retention of solutes that are 
normally cleared by healthy kidneys and secreted into the urine. 
The gradual retention of a large number of organic metabolites of 
proteins, fatty acids, and carbohydrates characterizes the 
progression of renal failure. 
Molecular weight is traditionally used as the parameter to classify 
uremic toxins, resulting in three groups of retention solutes: the 
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toxin class of low molecular weight (MW<500), middle molecular 
weight (500<MW<15000), and high molecular weight solutes 
(MW>15000). They can further be subdivided in protein-bound and 
nonprotein-bound solutes. Recently, an encyclopedic list of uremic 
retention solutes was composed by the European Uremic Toxin 
Work Group (EUTox), distinguishing between small molecules 
(MW<500), small protein-bound solutes (MW mostly <500), and 
middle molecules (MW>500) [134]. The main known uremic 
retention solutes are given in Table 1.3. 
At present, about 90 uremic retention solutes have been identified. 
Forty-five of them are small molecules without known protein 
binding. Twenty-five compounds belong to the group of protein-
bound solutes, with a molecular weight smaller than 500 Da, 
except two (i.e Leptin and Retinal-binding protein). From the 22 
recognized middle molecules, 12 have a molecular weight 
exceeding 15000 Da [134]. 
Table 1.3 Main known uremic retention solutes. 
Small water-soluble 
molecules  
Protein-bound 
solutes Middle molecules 
Creatinine Glyoxal β2-Microglobulin 
Guanidinosuccinic 
acid Hippuric acid β-Endorphin 
Hypoxanthine Homocysteine Cystatin C 
Methylguanidine Indoxyl sulfate Hyaluronic acid 
Malondialdehyde Kynurenic acid Interleukin 1β 
Oxalate Methylglyoxal Interleukin 6 
Urea p-cresol Leptin 
Uric acid Pentosidine Methionine-enkepahlin 
Xanthine Phenol Retinal binding protein 
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Low molecular weight molecules are water-soluble and are 
relatively easy to remove using standard low flux dialysis 
membranes. Because the removal of small protein-bound solutes is 
hampered due to protein binding, their dialytic behaviour is 
comparable to that of larger molecules. The so-called middle 
molecules can only be removed using high flux dialysis membranes 
with large pores, unless they are adsorbed on the membrane. 
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CHAPTER 2 
 
 
Clinical applications 
 
 
2.1 Warfarin and Oral Anticoagulant Theraphy 
 
Oral anticoagulant therapy (OAT) with coumarin derivatives such 
as warfarin, acenocoumarol and phenprocoumon, (also called 
vitamin K antagonists), extends the time it takes for the blood to 
clot, thereby reducing thromboembolic events in multiple clinical 
contexts [135]. These include atrial fibrillation, treatment of deep-
vein thrombosis, pulmonary embolism, prosthetic heart valves, and 
acute myocardial infarction. In fact, oral anticoagulant treatment 
has been available for more than 60 years, and is prescribed for 
both prophylactic and therapeutic use to patients at increased risk 
of thromboembolism. The relation between blood clotting and 
coumarin derivates was established by Dam and Doisy who shared 
the Nobel Prize in 1943 for their work [136, 137]. Their main 
discoveries were the postulation and prove of the existence of 
vitamin K (K for German Koagulation) and the description of 
structure of the vitamin. The fundamental physiological 
mechanism of affecting synthesis of certain coagulation factors was 
known, however, the biochemical description and understanding 
was yet to be established in the mid 70’s [138]. 
Both in Italy and around the world, patients receiving oral 
anticoagulant therapy are very numerous and tend to increase 
steadily in recent years. Reasons include improvements in clinical 
outcomes, increasing common disease indications for their use 
[139], and improvements in anticoagulant safety [140]. According 
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to an estimate of the Federazione Centri per la diagnosi della 
trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), 
which takes into account the market data of drugs and the average 
daily doses, in Italy there are about one million patients being 
treated with an oral anticoagulant [141]. Being the mainstream 
therapy for such a large range of indications, it is not surprising 
that warfarin is a widely used drug with increasing prescriptions 
over time. 
 
2.1.1 History of Warfarin 
 
The history of the discovery and development of coumarin 
anticoagulants randomly started in the United States at the end of 
1800 when farmers in North America experimented the sweet 
clover for the recovery of vast grasslands ravaged by herds of 
cattle. Shortly after, in 1921, a hemorrhagic epidemic spread, 
known as sweat clover disease, which decimated the cattle fed 
forage-rich clover. 
The disease continued though the 1920s and early 1930s. In 1933, 
Karl Link embarked on a study of the cattle disease at the 
University of Wisconsin. The research performed by Karl Link 
identified that the cause of such bleeding was not a contagious 
disease, viral or bacterial infection, but a chemical produced by a 
chemical reaction catalyzed by fungi of the genus Aspergillus. In 
1939 Link’s team crystallized the anticoagulant material [142]. 
Almost a year later the structure was identified and the chemical 
was synthesized [143] and named “dicumarol”. Soon, dicumarol 
was used throughout the world to prevent and to treat 
thromboembolic problems. 
In parallel with dicumarol’s introduction in clinical medicine, 
Link’s group synthesized over 150 of related coumarins looking not 
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so much for a better anticoagulant for human patients but rather 
for a more effective rodenticide. In 1948, one of those substances, 
number 42, was selected as a candidate for use as rodenticide in a 
project sponsored by the Wisconsin Alumni Research Foundation 
(WARF). The initial letters of the sponsor combined with “arin” 
(from coumarin) gave the compound its official name “Warfarin”. 
Being a highly potent (ten times more potent than dicumarol), 
water soluble anticoagulant without discernable taste or odour, it 
was easily delivered via cereal grain in doses high enough to cause 
lethal internal bleedings in the exposed rodents. 
Although the original oral anticoagulant dicumarol was an effective 
means of preventing thrombosis, researchers in the United States 
and Europe were continuously searching for more potent 
coumarins with faster onset of action, and a wider selection of 
administration routes. Since these properties were largely similar 
to those desired in a rodenticide, it is not entirely surprising that 
Link in 1950 proposed that warfarin should be tried as an 
antithrombotic. Equally unsurprising was the initial reluctance 
among clinicians to use warfarin in patients, given the fact that the 
substance was already a well-established rodenticide [144]. 
However, it’s reputation as a poisonous drug was somewhat 
mitigated in 1951, after a report of an army inductee failing to 
commit suicide by ingesting a packet of rat poison containing more 
than 500 mg of warfarin. 
In 1955, the drug’s reputation was further improved as the 
President Dwight Eisenhower of the United States was treated with 
this drug at a dose of 35 mg/week after a myocardial infarction 
and so he became one of the first famous patients on warfarin 
[145]. He would stay on this treatment until his death and it was 
only suspended for an operation for a bowel obstruction and a 
cholecystectomy. The treatment would not protect him against 
further heart attacks and a stroke. 
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Warfarin has since then not only become used as a highly effective 
rodenticide but also as the major oral anticoagulant for human 
thromboembolic diseases throughout the world [146] with nearly 
21.5 million prescriptions just in the USA in 2007 [147]. 
 
2.1.2 Physicochemical Properties of Warfarin 
 
Warfarin, C19H16O4, 3-(α-Acetonylbenzyl)-4-hydroxycoumarin 
(Figure 2.1) is a colourless crystalline material with a MW of 308.3 
and melting point between 159°C to 160°C. 
 
Figure 2.1 Chemical structure of warfarin 
The rigid and aromatic structure gives to warfarin a strong native 
fluorescence; thus it make possible fluorescence detection [148]. 
Warfarin is practically insoluble in water, moderately soluble in 
ethanol and readily soluble in acetone. 
Warfarin in the free acid form is not very soluble in water and is 
therefore always administered as the sodium salt. Warfarin 
sodium, C19H15NaO4 (MW: 330.32), (3-(α-Acetonylbenzyl)-4-
hydroxycoumarin sodium salt) is a white hygroscopic powder 
which is very soluble in water and in alcohols, soluble in acetone, 
very slightly soluble in ether and in methylene chloride. Warfarin 
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has an apparent dissociation constant (pKa) of 5.19 (at 25°C) and 
an octanol/water partition coefficient (log Pow) of 0.7 at pH=7, 20°C 
[149, 150]. 
Table 2.1 Physicochemical Properties of warfarin [150]. 
Property Value 
Solubility in water at 20 °C 267 mg/L 
Solubility in organic solvents 
at 20 °C 
Acetone: 54600 mg/L 
n-Heptane: 6.4 mg/L 
Methanol: 22200 mg/L 
Ethyl acetate: 16900 mg/L  
Melting point 165 °C 
Log P at pH=7, 20°C 0.7 
pKa at 25 °C 5.19 
Vapour pressure at 25 °C 3.0 mPa 
Henry’s law constant at 25 °C 3.50 10-3 Pa m3 mol-1  
Warfarin is a chiral molecule. The asymmetric carbon at position 9 
of warfarin gives rise to two enantiomers, namely R-(+)-warfarin (R-
warfarin) and its mirror image isomer S-(-)-warfarin (S-warfarin) 
(Figure 2.2). The main monohydroxylated metabolites of warfarin, 
such as 4’-, 6-, 7- and 8-hydroxywarfarin, also contain a single 
asymmetric centre (Table 2.2) [151]. 
MIRROR 
   
                           (S)(-)                                           (R)(+) 
Figure 2.2 Three dimensional structures of warfarin enantiomers. 
Clinical applications 
 
 
 
47
Table 2.2  Structures of warfarin and its main metabolites. Adapted from 
[152]. 
 
Compound 
Functional groups structure 
R1 R2 R3 R4 R5 R6 
Warfarin H H H H H 
 
6-Hydroxywarfarin OH H H H H 
 
7-Hydroxywarfarin H OH H H H 
 
8-Hydroxywarfarin H H OH H H 
 
4’-Hydroxywarfarin H H H OH H 
 
10-Hydroxywarfarin H H H H OH a 
 
Warfarin alcohol H H H H OH 
 
Note: *: Asymmetric centre; a: The second asymmetric centre generated at C-10 position. 
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2.1.3 Clinical Use of Warfarin 
 
In the clinical setting, warfarin is administered for the prevention 
and treatment of venous thrombosis and pulmonary embolism 
[135]. It is also used for the prophylaxis and treatment of 
thromboembolic complications associated with atrial fibrillation, 
diabetes mellitus and hypertension associated with an otherwise 
normal heart. It is additionally used as an adjunct in the treatment 
of coronary occlusion. Warfarin does not affect established thrombi 
or reverse tissue ischemia but is instead used to prevent clot 
growth and secondary complications [135]. Thromboembolism 
remains a serious complication after heart valve replacement 
whether the prosthesis is a mechanical valve or a valve of 
bioprosthetic tissue. Relatively intensive anticoagulant treatment is 
recommended with mechanical valve replacement, and therapy is 
depending on valve type and position [153]. Bioprostheses do not 
always require OAT, but patients are often anticoagulated for a 
period of 3-6 months, and with less intensity compared to 
treatment of patients with mechanical heart valve replacement 
[154]. Atrial fibrillation is one of the relatively new major patient 
groups who receive OAT to prevent formation of clots due to 
abnormal blood flow caused by the fibrillation [155]. Acute 
myocardial infarction and treatment with anticoagulants have been 
discussed since introduction of the treatment for this clinical 
condition. The prophylaxis treatment of this is often combined with 
aspirin [156]. The optimum duration of oral anticoagulant therapy 
is influenced by whether thrombosis is unprovoked (idiopathic), 
associated with ongoing risk factors (such as malignancy), or is 
secondary to a reversible cause; a longer course of therapy should 
be given for idiopathic thrombosis [157] and when there is an 
ongoing risk factor. Treatment should also be longer in patients 
Clinical applications 
 
 
 
49
with proximal vein thrombosis than in those with distal thrombosis 
and in patients with recurrent thrombosis vs those with a single 
episode. Other areas where OAT is applied are post-surgery, e.g. 
knee or hip replacement, and hereditary diseases such as 
thrombophilia. 
The ranges of International Normalized Ratio (INR) recommended 
by the British Society of Haematology are shown in table 2.3. 
Table 2.3 Recommended Therapeutic Range for Oral Anticoagulant 
Therapy. 
Indications  INR 
Prophylaxis of deep vein thrombosis 
(high risk surgery) 2.0 – 2.5 
Treatment of deep vein thrombosis, 
pulmonary embolism, atrial 
fibrillation 
2.0 – 3.0 
Recurrent deep vein thrombosis and 
pulmonary embolism 
3.0 – 4.5 Arterial disease (myocardial 
infarction, arterial grafts) 
Cardiac prosthetic valves and grafts 
 
2.1.4 Pharmacodynamics of Warfarin 
 
Warfarin produces an anticoagulant effect by interfering with the 
cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K 
epoxide) (Figure 2.3) [158]. Vitamin K is reduced (to vitamin KH2) 
either by a NADH dependent reductase activity, reaction ‹1›, or a 
reductase reaction dependent on the conversion of dithiol into 
disulfide, ‹3› (shaded). The carboxylation reaction, ‹2›, which 
converts glutamate residues (Glu) into γ-carboxyglutamate 
residues (Gla) on the N-terminal regions of vitamin K–dependent 
Clinical applications 
 
 
 
50
proteins, requires molecular oxygen and carbon dioxide, and is 
driven by a vitamin hydroquinone (KH2) dependent carboxylase 
activity. This activity simultaneously converts vitamin KH2 into 
vitamin K epoxide. The last step in the vitamin K cycle, reaction ‹3›, 
is a reductase of vitamin K epoxide dependent on conversion of 
dithiol into disulfide. 
 
 
Figure 2.3 A diagram of the actions involved in the vitamin K cycle and  
the site of action of oral anticoagulants. 
Warfarin acts by a partly or complete block of two different steps in 
the vitamin K cycle [159]: the two reactions indicated by ‹3› in 
Figure 2.3. When vitamin K hydroquinone (VKH2) availability is 
decreased, the vitamin K-dependent carboxylation of glutamic 
acids is reduced. If this reaction is halted, only a limited amount of 
vitamin K epoxide will be available for recycling of vitamin K by the 
enzyme Vitamin K epoxide reductase complex subunit 1 (VKORC1) 
[160]. 
This leads to synthesis of proteins induced by vitamin K absence, 
i.e. coagulation factors (II, VII, IX, and X) missing a carbon chain 
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and unable to function in the coagulation cascade [161]. In 
addition to their anticoagulant effect, the vitamin K antagonists 
inhibit carboxylation of the regulatory anticoagulant proteins C 
and S and therefore have the potential to exert a procoagulant 
effect. Synthesis of functional vitamin K dependent coagulation 
factors now becomes dependent on new sources of vitamin K. 
Warfarin does not alter the degradation rate of clotting factors 
already in circulation; it only affects the synthesis rate of clotting 
factors. Therefore, the onset of anticoagulation induced by warfarin 
is delayed. The anticoagulation effect of warfarin takes about 8 
hours to become apparent as a result of the time taken for 
degradation of carboxylated factors [162]. The onset of action of 
warfarin depends on the elimination half-lives of the relevant 
factors. Factor VII, with half-life of 6 hours, is affected first, then 
Factors IX, X and II with half-lives of 24, 40 and 60 hours, 
respectively [163]. The two enantiomers of warfarin display 
different anticoagulant potency in humans. S-warfarin is 
considerably more potent than R-warfarin in terms of the 
anticoagulant effect [162]. 
The anticoagulant effect of coumarins can be overcome by low 
doses of vitamin K1 (either ingested in food or administered 
therapeutically) because vitamin K1 bypasses vitamin K epoxide 
reductase (Figure 2.3). Patients treated with large doses of vitamin 
K1 (usually > 5 mg) can become resistant to warfarin for up to a 
week because vitamin K1 accumulating in the liver is available to 
bypass vitamin K epoxide reductase. 
Warfarin also interferes with the carboxylation of γ-
carboxyglutamate proteins synthesized in bone [164]. Although 
these effects contribute to fetal bone abnormalities when mothers 
are treated with warfarin during pregnancy [165], there is no 
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evidence that warfarin directly affects bone metabolism when 
administered to children or adults. 
 
2.1.5 Pharmacokinetics of Warfarin 
 
Warfarin is a racemic mixture of 2 optically active isomers, the R 
and S form, in roughly equal proportion. In studies that 
administered warfarin enantiomers separately, it was found that 
the S-enantiomer exhibits two to five times more anticoagulant 
activity than the R-enantiomer in humans but generally has a 
more rapid clearance [166]. Furthermore Chan et al [162] found 
that the anticoagulant effect of warfarin is predominantly 
contributed by S-enantiomer when warfarin was administered as 
rac-warfarin. 
Warfarin is essentially completely absorbed from the 
gastrointestinal tract after oral administration and has a systemic 
bioavailability of more than 90% in humans [162]. The maximal 
blood concentration in healthy volunteers is generally achieved 
within 60–90 minutes after oral administration.  
Once in the systemic circulation, warfarin’s distribution to other 
tissues is very limited as indicated by a small volume of 
distribution (VD), approximately 10 liters in an individual weighing 
70 Kg [167]. 
Although this volume does not refer to any actual body fluid or 
space, it provides a measure of a drug’s propensity to remain in the 
plasma, rather than being distributed to other parts of the body. 
This is of interest, since the body’s systems for elimination of drugs 
usually only target drug residing in plasma. Hence, drugs with a 
smaller VD tend to be cleared more rapidly, all other factors equal. 
Racemic warfarin has a half-life of 36 to 42 hours. 
Approximately 99.5% of the warfarin is bound to human plasma 
serum proteins, primarily albumin, where it is pharmacologically 
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inactive and is protected from biotransformation and excretion 
[168]. 
Warfarin accumulates in the liver, where the 2 isomers are 
metabolically transformed by different pathways to inactive 
hydroxylated metabolites (predominant route) and also by 
reductases to reduced metabolites (warfarin alcohols). While S-
warfarin is almost exclusively metabolized by the polymorphic 
cytochrome P450 2C9 (CYP2C9) enzyme, R-warfarin is metabolized 
by a wide range of cytochrome P450 enzymes, including CYP3A4, 
CYP2C19 and CYP1A2 (but not CYP2C9) [169]. 
Hepatic metabolism of warfarin is the major determinant of inter-
subject variability in the warfarin dose-concentration-response 
relationship. Warfarin is metabolized in a complex manner 
involving: (1) keto reduction resulting in the formation of four 
diastereoisomeric metabolites designated as warfarin alcohols; (2) 
oxidation to yield regioisomeric 4’-, 6-, 7-, 8- and 10 
hydroxywarfarin; (3) dehydration of warfarin alcohol to the cyclic 
metabolite and (4) various conjugation reactions [170]. The 
warfarin alcohols have minimal anticoagulant activity. Table 2.2 
shows the structures of warfarin and its main metabolites. 
Both reductive and oxidative metabolites of warfarin are principally 
excreted into the urine (≈ 80%) and, to a lesser extent (≈ 20%), into 
the faeces while enterohepatic circulation has been observed for 
the parent drug. Only 2-5% of the warfarin administered appears 
unchanged in human urine. 
 
2.1.6 Monitoring of Warfarin effect 
 
Coumarin anticoagulation needs to be strictly monitored because 
of the narrow therapeutic area between under- and over-
anticoagulation. In case of under-anticoagulation the patient is at 
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risk for thromboembolic complications and in case of over-
anticoagulation there is an increased risk of severe bleeding 
problems. Therefore, patients taking warfarin require frequent 
monitoring to adjust the dose in response to different interactions 
by food, drugs and illness [171, 172, 173]. This necessary 
monitoring represents an expensive investment for health care 
systems and an inconvenience for patients. Despite a close 
monitoring of therapy, thromboembolism and bleeding are common 
concerns and accounts for a large proportion of the morbidity and 
mortality in these patients: major bleedings have an incidence 
ranging from 0.3 – 13.4 % per year and that of major 
thromboembolism ranging from 0.4 – 3.5 % per year [174, 175], 
though highly dependent on selection of patients and definition of 
events. 
A number of methods can be used to measure the effect of warfarin 
in individuals, including the measurements of vitamin K1 and 
vitamin K1 2,3 epoxide concentration [176], γ-carboxyglutamic acid 
concentration [177] and clotting factor concentrations. Of the 
various methods available, the PT test or INR test is the most 
common method for monitoring the effect of oral anticoagulants 
[135]. The PT is responsive to depression of three of the four 
vitamin K-dependent procoagulant clotting factors (II, VII and X), 
that are reduced by warfarin at a rate proportional to their 
respective half-lives. Thus, during the first few days of warfarin 
therapy, the PT reflects mainly reduction of factor VII, since this 
factor has the shortest half-life (≈ 6 hours) among the vitamin K-
dependent factors. Subsequently, reduction of factors X and II 
contributes to prolongation of the PT. The PT assay is performed by 
adding calcium and thromboplastin to citrated plasma (Equation 
2.1): 
Citrated plasma + Thromboplastin + CaCl2 → Fibrin Clot         (2.1) 
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The traditional term “thromboplastin” refers to a phospholipid-
protein extract of tissue (usually lung, brain, or placenta) that 
contains both the tissue factor and phospholipid necessary to 
promote activation of factor X by factor VII. Thromboplastins vary 
in responsiveness to the anticoagulant effects of warfarin according 
to their source, phospholipid content, and preparation [178]. 
The responsiveness of thromboplastins can be measured by 
assessing their International Sensitivity Index (ISI). Difference in 
thromboplastin responsiveness was the main reason for clinically 
important differences in oral anticoagulant dosing. In 1983, the 
INR system proposed by Kirkwood was adopted by the World 
Health Organization (WHO) which then made international PT 
standardisation possible [179]. The calculation of INR is described 
in Equation 2.2. 
INR = (patient PT/mean normal PT)ISI      (2.2) 
where ISI denotes the International Sensitivity Index of the 
thromboplastin used at the local laboratory to perform the PT 
measurement. 
Warfarin dosing may be separated into initial and maintenance 
phases. An anticoagulant effect is observed within 2 to 7 days after 
beginning oral warfarin, according to the dose administered. When 
a rapid effect is required, heparin should be given concurrently 
with warfarin for ≥ 4 days. The common practice of administering a 
loading dose of warfarin is generally unnecessary, and there are 
theoretical reasons for beginning treatment with the average 
maintenance dose of ≈ 5 mg daily. 
When treatment is initiated, there is a large uncertainty regarding 
the individual dose requirements and to avoid prolonged over- or 
underdosing, the INR is usually checked daily until the therapeutic 
range has been reached and sustained for 2 consecutive days, then 
2 or 3 times weekly for 1 to 2 weeks, then less often, according to 
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the stability of the results. Once the INR becomes stable, the 
frequency of testing can be reduced to intervals as long as 4 weeks. 
The effectiveness and safety of warfarin therapy are critically 
dependent on maintaining the INR in the therapeutic range. 
 
2.1.7 Factors influencing oral anticoagulant therapy 
 
Drug interactions 
 
The term drug interaction refers to a situation were the effect of a 
drug is altered by another drug, an herbal medicine or by food. The 
interaction can result in either increased or decreased 
pharmacologic effect of the drug, as well as an altered risk of 
specific side-effects. Clinically important drug interactions occur 
when either of the interacting drugs have a steep concentration-
response curve and narrow safety margin such that a small change 
in plasma concentration leads to a substantial change in beneficial 
or adverse effect [180]. 
Drug interactions involving warfarin are exceedingly common. 
There have been more than 250 compounds proven to or suspected 
of having an interaction with warfarin [181]. One reason for this 
abundance is of course warfarin’s narrow therapeutic range, where 
even minor changes in drug concentration or drug sensitivity can 
have major clinical consequences. Another factor that is likely to be 
of importance is the elimination of S-warfarin being heavily 
dependent on a single liver enzyme (CYP2C9), making it vulnerable 
to pharmacokinetic drug interactions targeting this phatway. 
Understanding the mechanism of warfarin drug interactions 
provides an insight into the possible clinical significance of an 
interaction and can help elucidate strategies to avoid or minimise 
the impact in a given patient. 
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Drug interactions with warfarin can occur via two main 
mechanisms: 
1. Pharmacodynamic interactions: modification of the 
pharmacological effect of warfarin without altering its 
concentration in the body; 
2. Pharmacokinetic interactions: alteration of the concentration 
of warfarin reaching its site of action.  
 Pharmacodynamic warfarin interactions include drug and food 
containing vitamin K or altering the turnover of vitamin K, and 
antithrombotic drugs such as aspirin, that increases the risk of 
bleeding by inhibition of platelet aggregation in the blood [182, 
183]. 
Pharmacokinetic mechanisms for drug interactions with warfarin 
comprise mainly of induction or inhibition of drug metabolising 
enzymes and to a lesser extent alteration of plasma protein 
binding. 
Some drugs, e.g. the lipid-lowering agent cholestyramine, reduce 
the absorption of warfarin in the gut, thereby attenuating its 
anticoagulant effect. Drugs that bind extensively to albumin may 
displace warfarin from its binding sites on the plasma protein, 
thereby increasing the unbound concentration and the 
anticoagulant effect [184], but the effect is only transient and 
rarely of clinical importance. The most important pharmacokinetic 
interaction mechanism is altered hepatic metabolism of warfarin 
due to inhibition or induction of cytochrome P450 enzymes, 
CYP2C9 in particular. Important inhibitors of warfarin metabolism 
include e.g. the antiarrhythmic drug amiodarone and several azole-
type antifungals, while inducers such as the anti-tubercolosis 
agent rifampicin and several anti-epileptic drugs may vastly 
increase the warfarin dose required for adequate anticoagulant 
effect. 
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Genetic variations 
 
Mutations in the gene coding for warfarin metabolism enzymes 
have been shown to alter the response to warfarin treatment, thus 
increasing inter-individual INR variation. Some of the best 
documented wild types of CYP2C9*1 is CYP2C9*2 and CYP2C9*3 
[185]. These mutations are associated with an impaired ability to 
metabolize warfarin, hence prolonging warfarin half-life and 
leading to reduced warfarin requirements. Screening for gene-
mutations before initiating warfarin treatment is an ongoing 
discussion, but the relation between the mutations and higher risk 
of bleeding has been established [186, 187]. The VKORC1 enzyme 
is the target for warfarin’s inhibitory effect on the vitamin K cycle. 
Mutations in this gene have shown to account for some of the 
difficulties to maintain INR at target level [188]. Whereas of three 
well-described wild types of CYP2C9, there is a higher degree of 
diversity in mutations on VKOR1C; some leads to warfarin 
resistance, while others lead to reduced VKOR activity [189]. Fifty 
percent of the inter-individual variation on warfarin response is 
believed to be directly accounted for by the pharmacokinetic 
variants (CYP2C9) and pharmacodynamic variants (VKORC1) [190]. 
A population based model of different types of genetic mutations 
and warfarin treatment showed the effect of different combination 
of wild type alleles. The model showed how equal dose of warfarin 
could potential lead to an INR value of 2 in one patient, and an INR 
value above 6 in another patient solely depending on gene 
mutations [191]. 
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Dietary vitamin K 
 
OAT can be affected by numerous environmental factors that can 
alter warfarin kinetics and dynamics [182]. Vitamin K dietary 
intake is one of these factors, which may alter the response to 
warfarin treatment. New external sources of vitamin K will increase 
the production of functional coagulation factors depending on 
vitamin K. The clinical relevance of changes in vitamin K has been 
discussed, and it has been shown how patients with poor dietary 
intake of vitamin K often has less stable control of anticoagulation 
[192]. It has been suggested to provide these unstable 
anticoagulated patients with oral vitamin K supplementation; 
however unrecognized intake of such can lead to warfarin 
resistance [193]. Other studies reported that steady-state warfarin 
treatment was not affected by dietary vitamin K intake [194, 195]. 
However, Khan and colleagues suggested that their findings, of 
vitamin K having no effect in their regression model, could be 
related to the fact that warfarin dosage had already been adjusted 
to control for individual vitamin K status. Further, they only 
involved patients whose dose of warfarin remained constant. 
Variations in vitamin K might be greater in patients who do not 
receive an optimized warfarin dose that remains constant. 
Although Loebstein and colleagues reported vitamin K as 
negligible; a recently published review by the same research group 
acknowledges that vitamin K plays an important role in 
maintaining therapeutic stability [196]. The magnitude of clinically 
relevant change in dietary vitamin K intake has been reported to be 
above 100 mg/day [197]. 
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2.1.8 Approaches to counter challenges in OAT 
 
Approaches to improve anticoagulant control include, among 
others, development of new antithrombotic drugs, use of different 
types of management of the treatment, and use of computer 
software that can aid in dose adjustment. 
 
Development of new antithrombotic drugs 
 
Through the last decade researchers have been working on 
development of a new type of antithrombotic drug, which could 
eliminate or minimize the difficulties in warfarin treatment: the 
relatively narrow therapeutic window, large inter-individual dose 
response, drug-to-drug interactions, and the need for close 
monitoring that is associated with the fear of adverse events of 
over-treatment. Direct thrombin inhibitors are a newly developed 
class of anticoagulants that acts by directly inhibiting activated 
clotting factor II. Another type of newly developed drug class is 
direct clotting factor X inhibitors [198, 199]. Both drug classes can 
be given in a fixed dose and does not require routine monitoring. 
Large-scale randomized controlled trials have been conducted with 
different types of commercially available analogues, and the usage 
has been explored in different clinical conditions [200, 201, 202]. 
 
Types of OAT management 
 
The introduction of portable monitors (point-of-care devices) for the 
management of patients on oral anticoagulation allows the patient 
to self-test at home with a drop of whole blood. Portable monitors 
for monitoring long-term oral anticoagulation were introduced in 
the 1990s. POC monitors measure a thromboplastin-mediated 
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clotting time that is then converted to a plasma PT equivalent by a 
microprocessor and expressed as a PT or INR. Portable monitors 
have proved to be reliable with regard to analytical accuracy, 
although INR measurements tend to be lower with the portable 
coagulometers compared to laboratory analysers [203, 204]. 
Generally patients receive a structured educational programme 
given by the nurses or physicians responsible for their care. In 
addition, they receive training in self-testing, instructions to 
prevent bleeding and thromboembolic complications, and are made 
aware of the effects of diet and medications [205]. 
Patients who self-test can either adjust their therapy according to a 
pre-determined dose-INR schedule (self-management) or they can 
call a clinic to be told the appropriate dose adjustment (self-
monitoring). Several trials of self-monitoring of oral anticoagulant 
therapy suggest this may be equal to or better than standard 
monitoring [206, 207]. 
There are several available point-of-care devices and the most well 
known is the CoaguChek® monitor. Other available monitors are 
the ProTime® Microcoagulation System, INRatio® Monitor, 
Hemochron Junior Signature, and the TAS near-patient test 
system. Potential advantages of self-monitoring and self-
management include improved convenience for patients, better 
treatment adherence, more frequent monitoring, and fewer 
thromboembolic and haemorrhagic complications [208, 209]. 
 
Decision support systems 
 
Computer programs with algorithms capable of predicting the next 
warfarin dose (or response to a future warfarin dose), can 
potentially aid poorly controlled dose management in OAT. Such 
systems are based on different approaches ranging from strict 
expert-based algorithms, population- based 
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pharmacokinetic/pharmacodynamic (PK/PD) models, and rigid 
mathematical methods such as regression modelling. Bayesian 
parameter optimization methods are common techniques in the 
latter two approaches, and are meant to account for inter- and 
intraindividual response to vitamin K antagonists [210]. 
Through the past 25 years computerized decision support systems 
(CDSS) have been available to assist clinicians in OAT. Some of the 
first studies have shown that such systems can be at least as 
effective as experienced physicians with regard to dose adjustment 
[211, 212, 213]. In a large scale multicenter randomized trial Poller 
and colleagues showed the effective use of the computer program 
DAWN AC [214]. The computer program gave significantly better 
INR control compared to physician management. Another approach 
by Manotti and colleagues using the software program PARMA 
(later PARMA 5) achieved similar results as the DAWN AC study; 
even though they obtained a slight higher Time (spent) in 
Therapeutic Range (TTR) [139, 215]. Poller and colleagues 
conducted yet another multicentre randomized study comparing 
the use of DAWN AC and PARMA 5 in different countries [216]. 
This proved that computer-assisted dosage could be both safe and 
effective. However, the American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines (8th Edition) do not 
directly recommend use of CDSS, and the guidelines state that it 
should be based on physician preferences [217]. 
Pending instrumental self-monitoring solutions easier to use and 
cheaper, or pharmacological solutions more effective and 
independent of external factors (lifestyle, diet, medication, etc.), a 
certain advantage for patients undergoing anticoagulant oral 
therapy with warfarin may be to carry out their monitoring in 
biological matrices alternatives to blood. In the case of oral fluid, 
an obvious advantage is the non-invasiveness of sampling resulting 
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in a direct and immediate relief of the patient. Contrary to the 
blood, the collection of biological fluids such as oral fluid can be 
performed without special equipment, even in the case of less 
cooperative patients such as children or elderly. 
Furthermore, we believe it possible to find in the oral fluid useful 
information relevant to the coagulation level, with a potential 
clinical interest both for a deeper understanding of warfarin action 
and patient monitoring. 
Since oral fluid is a matrix far less complex than blood, in case of 
success it is not unreasonable to imagine that the determination of 
warfarin concentration in oral fluid could become a non-invasive 
test enabling the efficacy and safety of warfarin therapy to be 
monitored by the patient itself in the time span between two 
conventional INR checks. 
Thus, a non-invasive method providing information on the 
anticoagulation level, potentially implementable in low cost devices, 
could modify the present management of anticoagulation therapy 
and make warfarin more attractive in a moment when a new 
generation of drugs is appearing on the market. 
 
2.2 Monitoring of volatile compounds in human 
breath 
2.2.1 Diabetes mellitus 
 
Diabetes mellitus is a group of metabolic diseases characterized by 
high glucose levels in blood (hyperglycaemia), that result from 
defects in insulin secretion, or action, or both [218]. Insulin is the 
hormone, produced by the pancreas, which permits glucose to 
enter into cells and to be used as source of energy. When this 
mechanism is altered, glucose accumulates in the blood 
circulation. Once the glucose haematic and renal threshold has 
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been exceeded, the effects of glycosuria (glucose in urine) and 
polyuria (loss of water and electrolytes) appear and give rise to 
polydipsia (increased thirst) and polyphagia (increased hunger). 
The organism therefore tries to produce glucose through other 
metabolic pathways such as lipolysis (fat acids oxidation), which 
causes an increase in ketone bodies in blood (acetone, β-
hydroxybutyric acid, acetoacetic acid). 
There are two main types of diabetes: 
1) Type 1 diabetes, formerly known as insulin-dependent 
diabetes mellitus (IDDM) or juvenile-onset diabetes, is 
caused by autoimmune destruction of the β-cells of the 
pancreas, rendering the pancreas unable to synthesize and 
secrete insulin [219]. 
2) Type 2 diabetes, formerly known as non-insulin-dependent 
diabetes mellitus (NIDDM) or adult-onset diabetes, results 
from insulin resistance, a condition in which cells fail to use 
insulin properly, sometimes combined with an absolute 
insulin deficiency [220, 221].  
The diagnosis of diabetes is based on the results obtained by 
specific medical examinations besides on the clinical symptoms 
[218]. The oral glucose tolerance test (OGTT) is a diabetes 
diagnostic test which monitors glycaemia in the subsequent hours 
after dispensing a known amount of glucose (150 mL of a 50% 
glucose solution). After dispensing glucose, glycaemia rises. Within 
two hours, in subjects without diabetes, glycaemia reduces to 140 
mg/dL; if this doesn’t happen the OGT is considered positive and 
diabetes is diagnosed. 
Chemical composition of exhaled air reflects the general metabolic 
conditions and it may give useful information on the state of health 
of a person. For these reasons we investigated the possibility of 
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diagnosing diabetes mellitus by non-invasive monitoring of volatile 
compounds in exhaled breath during the oral glucose tolerance 
test (OGTT). 
 
2.2.2 Volatile anaesthetic agents: sevoflurane 
 
Recently two new inhalant anaesthetic agents were commercialised 
in Europe, sevoflurane and desflurane. Both agents fit the mould of 
several other new anaesthetic agents and adjuvants. They permit 
greater control over the course of anaesthesia and more rapid 
recovery from anaesthesia than do their predecessors. 
Sevoflurane was developed in the seventies [222] and since 1980 it 
is extensively examined in human and veterinary anaesthesia, 
especially on an experimental basis in the beginning. Since 1990 it 
can be used in clinical human anaesthesia. 
 
2.2.2.1 Physicochemical Properties of Sevoflurane 
 
The chemical structure of inhalation anaesthetics and their 
physical properties are important determinants of their actions and 
safety of administration. 
Sevoflurane (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane, 
C4H3F7O) is a colourless, volatile, non-flammable liquid with a 
characteristic mild odour resembling ether. Chemically, 
sevoflurane is a polyfluorinated methyl isopropyl ether (Figure 2.4) 
with 7 fluorine atoms and a molecular weight of 200.05. The 
chemical structure of sevoflurane is responsible for its kinetic 
properties. 
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The boiling point (58.6 °C) and vapour pressure (157 mmHg at 20 
°C) of sevoflurane are comparable with those from halothane, 
isoflurane and enflurane. Hence, conventional precision vaporisers 
without specific technical requirements can be used [227]. 
The most common measure of anaesthetic potency of an inhalation 
anaesthetic is the minimum alveolar concentration (MAC) of 
anaesthetic in volumes (percentage) which are necessary to prevent 
movement in 50% of patients during skin incision [228]. As is the 
case with other inhalational anaesthetics, the anaesthetic potency 
of sevoflurane is correlated with its lipid solubility. With an oil/gas 
partition coefficient of 47.2 its MAC has been reported to be 2.05% 
[229]. Thus its anaesthetic potency is about 50% less than that of 
isoflurane but 30% more than that of desflurane. Sevoflurane is 
readily degraded by carbon dioxide absorbents to haloalkene 
byproducts that are nephrotoxic in rats, but there is no evidence of 
such toxicity in humans. In contrast to some other inhalation 
anaesthetic agents, which are degraded by carbon dioxide 
absorbents with generation of carbon monoxide, sevoflurane 
degradation generates negligible quantities of carbon monoxide. 
 
2.2.2.2 Pharmacokinetic Properties of Sevoflurane 
 
The uptake of a volatile anaesthetic is described by the rate of 
increase of the FA/FI ratio; conversely, its elimination is described 
by the rate of decrease of the FA/FA0 ratio, where FA is the alveolar 
concentration of anaesthetic (measured at the end of expiration), FI 
is the inspired anaesthetic concentration and FA0 is the alveolar 
concentration of the anaesthetic immediately before termination of 
its application [230]. 
In general, there is an inverse relationship between the blood/gas 
partition coefficient of a given volatile anaesthetic and the time 
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required until the alveolar and inspired concentrations are in 
equilibrium. 
The alveolar equilibration of sevoflurane is rapid, 80% complete 
within 30 minutes, compared with that of isoflurane (73%) or 
halothane (58%) but not desflurane (90%) [231, 232]. The 
estimated tissue distribution of sevoflurane is similar to that of 
isoflurane. 
Similar to uptake, the elimination of a given volatile anaesthetic is 
related to its solubility in blood and tissue. Between 95 and 98 % 
of the amount of sevoflurane taken up is eliminated through the 
lungs [230]. 
Sevoflurane is eliminated faster than isoflurane despite its greater 
blood/tissue partition coefficient. Thus, the wash-out of 
sevoflurane in the first 2 hours after discontinuation of 
anaesthesia is 1.6-fold more rapid than with isoflurane but slower 
than desflurane. Mean pulmonary elimination clearance of 
sevoflurane (3.58 L/min) is not significantly different from that of 
isoflurane (3.62 L/min), and total body clearance of both agents is 
identical (3.6 L/min).   
Sevoflurane undergoes dose-independent hepatic 
biotransformation, principally by cytochrome P450 (CYP) 2E1, with 
1 to 5% of the absorbed dose of sevoflurane undergoing 
metabolism to liberate inorganic fluoride ions (F-) and 
hexafluoroisopropanol (HFIP) as the principal byproducts [233]. 
The latter compound accounts for 82% of the organic fluorinated 
metabolites. HFIP is rapidly glucuronidated and then undergoes 
rapid urinary excretion. Sevoflurane, unlike methoxyflurane, 
undergoes minimal renal defluorination. 
Sevoflurane is eliminated directly via exhaled breath and indirectly 
by metabolic conversion at hepatic level to hexafluoroisopropanol 
(HFIP). Since this metabolite is also eliminated via the exhaled 
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breath, we hypothesized that the elimination kinetics of 
sevoflurane and HFIP could provide information on the liver 
function in a non-invasive way. Thanks to exhaled breath analysis, 
we studied the post-operative sevoflurane and HFIP elimination 
kinetics as a first step towards investigating the possibility of a 
non-invasive monitoring of the liver function in case of liver 
transplants. 
 
2.3 Monitoring of uremic toxins in spent dialysate 
2.3.1 Adequacy of hemodialysis 
 
Dialysis dose can be defined as the amount of hemodialysis 
received per dialysis and the dialysis frequency per week [234]. It is 
a measure of how effective a dialysis treatment removes waste 
products from the body [235]. 
The concept of dialysis adequacy was developed in the early 1970s 
to assess the treatment efficiency of end-stage renal disease 
(ESRD) patients [236]. 
From the very beginning the removal of small molecules was 
considered important as they were directly linked to the symptoms 
and signs of renal failure [237, 238]. Therefore, urea has been 
suggested as a surrogate marker for small toxic solutes. In 1975 
urea gained wide acceptance as a marker of solute removal in 
dialysed patients [239]. 
Two methods are generally used to assess dialysis adequacy: the 
Urea Reduction Ratio (URR) and the Kt/V. 
Urea Reduction Ratio (URR) 
The URR is a formula (equation 2.3), which expresses the 
reduction in blood urea during a dialysis session [234]. 
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URR = [(BUNPre-dialysis-BUNPost-dialysis)/BUNPre-dialysis]·100     (2.3) 
where BUN is the blood urea nitrogen. 
The URR is the simplest way to measure the delivered dialysis 
dose. It does not include the time of dialysis, the body size and 
effects of ultrafiltration [130]. Hence, the URR does not consider 
the residual renal function. The URR should be continuously 
higher than 65 % (with a three times per week HD schedule) to 
ensure an adequate treatment [240]. 
Normalised dose of dialysis (Kt/V) 
In 1985 Gotch and Sargent [241] introduced the Kt/V ratio as a 
result of their “mechanistic” analysis of the National Cooperative 
Dialysis Study (NCDS). The study was performed between 1976 
and 1981 in the USA with the aim to find a correlation between the 
dialysis dose and morbidity [237]. 
K represents the dialyser urea clearance (known from in-vitro 
studies), t is the dialysis time and V is the urea distribution volume 
[130]. The Kt/V value is the ratio between the volume of blood 
cleared of urea during a dialysis session (Kt) and the distribution 
volume of urea (V) which is equivalent to the total body water [242]. 
The gold standard for determining Kt/V in HD is by urea kinetic 
modelling (UKM) [242]. UKM is based on the principle of mass 
balance to describe urea nitrogen production and urea removal in 
the body [243]. 
The analysis of the NCDS by Gotch and Sargent revealed that a 
Kt/V < 0.8 (three times per week HD schedule) was associated with 
an increased morbidity. They concluded that a Kt/V of 1.0 was 
adequate [241]. Since then, there is a controversial discussion 
about the appropriate Kt/V value to ensure an adequate treatment 
[242]. The UK Renal Registry (2003) recommends a Kt/V value 
greater than 1.2 as an appropriate dialysis dose. 
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2.3.2 Monitoring of hemodialysis 
 
As mention above, the Kt/V value and the URR value are the most 
commonly used parameter to judge the adequacy of hemodialysis 
treatment. For both values, the determinations of pre- and post-
dialysis urea concentrations are necessary [130, 237]. The urea 
concentrations can be measured either on the blood side or on the 
dialysate side. 
In the past few years, several devices have been developed that can 
measure urea continuously in blood or in spent dialysate [237]. 
The majority of urea measurements are based on an enzymatic 
reaction. The enzyme urease catalyses the following reaction [244]: 
(NH2)2CO + 2H2O ֐ NH3 + NH4+ + HCO3-     (2.4) 
The amount of urea is measured indirectly by measuring the 
products of reaction in equation 2.4. This can be done by either 
measuring the breakdown products directly (NH4+) or indirectly by 
measuring a secondary parameter (pH, conductivity) [237, 244]. It 
is important, that enough urease is present to convert all of the 
urea. 
Current research is focused on the development of new urea 
kinetic models, in particular multi-compartment models to provide 
a more accurate estimate of the Kt/V value [236, 245, 246]. 
However, multi-compartment models require multiple blood tests 
to solve the complex equations. These difficulties preclude its use 
in routine clinical practice. 
Another area of research is based on the spectroscopic 
determination of urea and other small molecules retained in ESRD 
patients. Recently, two research groups published their results. 
Fridolin et al. [247] applied UV spectroscopy to measure small 
waste products in spent dialysate. This group observed a good 
correlation between the UV absorbance (285 nm) and the removal 
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of small molecules such as urea, creatinine and uric acid. Similar 
results were found by Olesberg and co-workers [248], who used an 
FTIR (Fourier Transform Infrared) spectrometer. They found, that 
the absorption spectrum of urea in the range between 5000 – 4000 
cm-1 (λ = 2.0 – 2.5 µm) is relative strong and distinct from other 
components. In both cases, the results need to be validated. 
Desire for a simple, compact, inexpensive, mobile and reliable 
method for estimating the efficiency of the dialysis has arisen due 
to increasing number of dialysis patients and related treatment 
quality requirements. Inspired by a wish to improve quality 
estimation of the dialysis, we followed the same research line of 
Fridolin group with the idea of non-invasive real time monitoring of 
the efficiency of hemodialysis from the analysis of spent dialysate. 
By optical monitoring of the spent dialysate it is possible to 
monitor the removal of several clinical important solutes associated 
with dialysis outcome. Therefore, there is a good possibility to 
develop an on-line monitoring system that can be a valid tool for 
clinicians to assess removal of uremic toxins and deliver 
personalized hemodialysis treatments. Furthermore, it can prevent 
serious pathological conditions, decrease mortality of patients and 
also alert immediately about any deviations in dialysis treatment. 
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CHAPTER 3 
 
 
Materials and Methods 
 
 
3.1 Chemical reagents 
 
Warfarin, i.e. 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt 
(purity ≥ 98%), sodium phosphate monobasic (purity ≥ 99.0 %), 
potassium phosphate dibasic (purity ≥ 99.0 %), urea, uric acid, 
creatinine and β2-microglobulin (purity ≥ 99.5 %) were purchased 
from Sigma-Aldrich (Milan, Italy). Pilocarpine hydrochloride and 
sodium nitrate were from Galeno (Comeana, Italy). Ethanol, 1-
propanol, 2-propanol, 1-butanol, ethyl acetate, 2-pentanone and 4-
heptanone were purchased from AccuStandard, Inc. Chemical 
Reference Standard (USA). Isoprene, acetone, acetonitrile, pentane, 
2-methylpentane, hexane, 1,1,1,3,3,3-hexafluoro-2-propanol, 
dimethylsulphide, dimethyldisulphide, 2,3-butanedione, acetoin, 
benzene, toluene, chloroform, carbontetrachloride, 
trichloroethylene, tetrachloroethylene and m-cresol puriss p.a. 
standard for GC grade > 99% were purchased from Fluka, Sigma-
Aldrich (Milan, Italy). Sevoflurane was from Abbott, Italy.  
Labelled isopropanol-D8 and toluene-D8 (purity 99.8 %) were 
purchased from ARMAR Chemicals (Switzerland). 
HPLC grade methanol, acetonitrile, hexane, and dichloromethane 
were purchased from ROMIL Super Purity Solvent (United 
Kingdom). Formic acid (purity 95-97 %) and sulphuric acid (purity 
95-98 %) were purchased from Sigma-Aldrich (Milan, Italy). Ultra 
pure water was produced by a Milli-Q Reagent Water System 
(Millipore, USA). 
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The thromboplastin reagent (HemosIL RecombiPlasTin 2G), 
thromboplastin diluent (HemosIL RecombiPlasTin 2G Diluent), 
calibration plasma, normal control assay, low and high abnormal 
control assays used for INR measurements and quality control 
were supplied from the Instrumentation Laboratory (Milan, Italy). 
All chemicals were used without any further purification. 
 
3.2 Preparation of standards 
 
1 L of phosphate buffer stock solution (1 M, pH 7.02) was prepared 
by dissolving 18.30 g of sodium phosphate monobasic and 49.21 g 
of potassium phosphate dibasic in water. The solution was filtered 
through a 0.45 μm membrane and after pH control was stored at 4 
°C. This solution was then diluted to 25 mM to obtain the 
phosphate buffer solution (PBS) used for HPLC analyses. 
A 1 mg/mL stock solution of warfarin was prepared by dissolving 
0.11 g of pure compound in 100 mL of water and stored at 4 °C 
until used. This solution was diluted with PBS to prepare a 10 
μg/mL standard solution that was further diluted with PBS to 
achieve 0.5, 1, 2, 5, 10, 20, 50 and 100 ng/mL standard working 
solutions. 
Pooled patient oral fluid samples (POFSs) were obtained by pooling 
samples from 20 patients. Control oral fluid samples (COFSs) were 
obtained from 10 volunteers who stated that they were not taking 
warfarin. Aliquots of COFS were spiked with known amounts of 
warfarin to obtain standard oral fluid samples (SOFSs) at different 
concentration levels. 
Pilocarpine hydrochloride and sodium nitrate solutions in water 
were prepared by dissolving the weighed reference compounds to 
achieve a concentration of 5 g/L and 10 g/L respectively. 
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Two mixtures were prepared by mixing 50 μL of twelve (MIX 12) 
and thirteen (MIX 13) pure liquid compounds respectively. Then a 
gaseous mixture (MIX 25) was obtained by introducing 10 μL of 
liquid MIX 12 and 10 μL of liquid MIX 13 into a 2 L glass flask 
equipped with a septum, pre-evacuated and held at 37 °C. The 
corresponding concentrations are reported in Table 3.1. 
A gaseous sevoflurane sample was prepared by evaporating 10 μL 
of liquid sevoflurane in a 2 L glass flask equipped with a septum, 
pre-evacuated and held at 37°C. The corresponding concentration 
was 954 ppmv. 
A gaseous mixture of labelled isopropanol-D8 and toluene-D8 (MIX 
2D), to be used as an internal standard, was prepared by 
evaporation of 5 μL of both compounds in a 2 L glass flask 
equipped with a septum, pre-evacuated and held at 37°C. The 
corresponding concentrations were 830 ppmv for isopropanol-D8 
and 600 ppmv for toluene-D8. 
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Table 3.1 Concentration of compounds in MIX 25. 
Analytes Glass flask concentration [ppmv] 
Pentane 85 
Ethanol 184 
Isoprene 98 
Acetone 133 
Dimethylsulphide 133 
2-propanol 128 
Acetonitrile 203 
2-methylpentane 74 
Hexane 75 
1-propanol 142 
2,3-butanedione 135 
Ethyl acetate 108 
Chloroform 132 
Carbontetrachloride 110 
Benzene 119 
1-butanol 116 
Trichloroethylene 119 
2-pentanone 92 
Hexafluoroisopropanol 94 
Dimethyldisulphide 109 
3-hydroxy-2-butanone 118 
Toluene 92 
Tetrachloroethylene 102 
4-heptanone 70 
m-cresol 93 
 
Stock solutions of uric acid, creatinine and β2-microglobulin, at a 
concentration of 1, 6 and 0.1 mg/mL respectively, were prepared 
by dissolving the weighed amount in water. Such solutions were 
diluted to a concentration of 50, 20 and 2 μg/mL for uric acid, 60, 
6 and 0.6 μg/mL for creatinine and 25, 10, 5 and 2 μg/mL for β2-
microglobulin to obtain standard working solutions. 
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A 10 mg/mL stock solution of urea was prepared by dissolving the 
weighed amount in water. 
A pooled patient dialysate sample was obtained by pooling aliquots 
of each patient sample collected 240 minutes after the beginning of 
the dialysis treatment. 
 
3.3 Instrumentation 
 
A iontophoretic equipment (New Ionoderm, Roversi Elettromedicali, 
Fiorano (Mo), Italy) was used for sweat stimulation. 
A centrifuge Centrifugette 4206 (ALC, Milan, Italy) and a centrifuge 
Allegra 21R equipped with a S4180 swinging bucket rotor 
(Beckman Coulter, USA) were used for samples centrifugation and 
ultrafiltration respectively. 
High performance liquid chromatography was carried out by a 
Jasco HPLC system (Jasco Europe, Italy) equipped with an 
autosampler (AS 2055), a quaternary low pressure gradient pump 
(PU 2089) and a spectrofluorimetric detector (FP 2020). The 
column temperature was controlled by a thermostat (HT 3000, 
ClinLab, Italy). The HPLC system was controlled by ChromNAV™ 
software from Jasco. 
To validate the analytical method for warfarin determination, few 
selected samples were also analyzed by a Micro HPLC system 
(Perkin Elmer Series 200) coupled with an autosampler (Series 
200) and a triple quadrupole mass spectrometer (Applied 
Biosystems Sciex API 365) operating in the Selected Reaction 
Monitoring (SRM) mode. The mass spectrometer was equipped with 
an Atmospheric Pressure Photo-Ionization (APPI) interface 
operating in negative ion mode. 
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The INR measurements were carried out at the clinical chemical 
laboratory of the Azienda Ospedaliero Universitaria Pisana (AOUP) 
by an automatic system (ACL TOP700, Instrumentation 
Laboratory) equipped with an autosampler. Spectrometric INR 
measurements were performed at a wavelength of 671 nm to 
minimize optical interference (e.g. hemoglobin and bilirubin). 
Absorption and fluorescence spectra were recorded by a 
spectrophotometer (Lamba 25, PerkinElmer, USA) and a 
spectrofluorimeter (LS 45, PerkinElmer, USA) respectively. 
A low flow Pocket Pump (210-1002TX, SKC, Italy) was used to 
transfer breath samples into adsorption tubes. 
Thermal desorption (TD) and GC-MS analysis were performed by 
an automated two-stage thermal desorption unit (STD 1000, DANI 
Instrument, Italy) equipped with an internal focusing trap packed 
with 70 mg of Tenax GR (DANI Instrument, Italy), a gas 
chromatograph (Trace GC Ultra, Thermo Electron Corporation, 
USA) and a quadrupole mass spectrometer (Trace DSQ, Thermo 
Electron Corporation, USA) operated in the positive electron impact 
(EI) ionization (70 eV) and Total Ion Current (TIC) and Selected Ion 
Monitoring (SIM) acquisition mode. The thermal desorption system 
was controlled by TD Manager™ software from DANI and the GC-
MS system was controlled by Xcalibur™ software from Thermo. 
 
3.4 Optimization of HPLC assay for warfarin 
determination 
3.4.1 Absorption and fluorescence spectra of 
warfarin 
 
Warfarin absorption and fluorescence spectra allowed to select the 
best wavelengths for the HPLC assay. Figures 3.1 and 3.2 show the 
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warfarin absorption spectrum in the range 220 – 440 nm and the 
warfarin fluorescence spectrum (excitation wavelength of 308 nm) 
in the range 330 – 590 nm, measured in a standard solution in 
PBS 25 mM at pH = 7 with a warfarin concentration of 10 μg/mL. 
 
Figure 3.1 Absorption spectrum of warfarin in PBS. 
 
Figure 3.2 Fluorescence spectrum of warfarin in PBS. 
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The absorption spectrum exhibits a maximum at about 310 nm. 
Fluorescence emission measurements were made at 400 nm (where 
a broad peak is observed) after excitation at a wavelength of 310 
nm. 
 
3.4.2 Selection of the mobile phase 
 
The optimization of the mobile phase was performed by using a 
standard working solution of warfarin and a SOFS with a warfarin 
concentration of 2.0 ng/mL. 
Because of the weakly acidic nature of warfarin (pKa = 5.19), a 
neutral mobile phase consisting of 25 mM phosphate buffer at pH 
= 7 and methanol as organic modifier was selected to obtain 
warfarin in the dissociated form, which is more prone to interact 
with the stationary phase. 
Standard working solutions of warfarin and SOFSs were analyzed 
by using mobile phases with different compositions. 
Chromatographic separation was carried out in isocratic conditions 
with a C-18 reversed-phase column Chromspher 5 PAH (Varian, 
150 × 4.6 mm, 5 μm), coupled with a guard column ChromSep SS 
(Varian, 10 × 2 mm), flow rate of 1.0 mL/min; injection volume of 
25 μL, column temperature of 25 °C and fluorescence detection 
with an excitation and an emission wavelength of 310 and 400 nm 
respectively. 
The best chromatographic separation was achieved by a mobile 
phase consisting of 28 % methanol and 72 % PBS (25 mM at pH = 
7). 
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3.4.3 Selection of the injection volume 
 
Increasing volumes (5, 10, 25 and 50 μL) of a standard working 
solution with a warfarin concentration of 20 ng/mL were analyzed 
to evaluate the effect of the injection volume on the peak shape. 
Chromatographic separation was carried out by the Chromspher 5 
PAH column in isocratic conditions with a 28 % methanol and 72 
% PBS (25 mM at pH = 7) mobile phase at a flow rate of 1.0 
mL/min; column  temperature of 25 °C and fluorescence detection 
with an excitation and an emission wavelength of 310 and 400 nm 
respectively. 
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Figure 3.3 HPLC chromatograms of a standard working solution of 
warfarin at different injection volumes:5 μL (black line), 10 μL 
(red line), 25 μL (blue line) and 50 μL (green line). 
The area of the warfarin fluorescence signal increased linearly (R2 = 
0.999) in the observed range of the injected volume (Figure 3.3). An 
injection volume of 25 μL was selected and used in all subsequent 
measurements. 
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3.4.4 Experimental conditions in method validation 
HPLC-fluorimetry 
A column Poroshell 120 EC-C18 (Agilent Technologies, 100 × 4.6 
mm, 2.7 μm) connected to a guard column TC - C18 (12.5 x 4.6 
mm, 5 μm, Agilent Technologies), was used to evaluate the 
presence of interfering substances. The mobile phase composition 
was optimized and resulted 35 % methanol and 65 % PBS (25 mM 
at pH = 7) at a flow rate of 0.7 mL/min and 25°C. 
HPLC-MS/MS 
Comparative measurements were performed on standard working 
solutions of warfarin and SOFSs by HPLC-MS/MS. 
Chromatographic separation by the Perkin Elmer HPLC system 
was carried out in isocratic conditions on a C-18 reversed-phase 
column Chromspher 5 PAH coupled with a guard column 
ChromSep SS. A 50 % acetonitrile, 50 % water containing 0.1 % 
formic acid mobile phase was used at a flow rate of 1 mL/min and 
25 °C. Warfarin was quantified by the mass spectrometric detector 
observing the following two ion transitions (expressed by their 
mass number/charge number ratios): m/z 307 → 161 and m/z 
307 → 250. 
 
3.5 Thermal desorption gas chromatography mass 
spectrometry (TD-GC-MS) assay for breath 
analysis 
 
Gas chromatographic separation was performed by a 6% 
cyanopropyl phenyl siloxane and 94% dimethylpolysiloxane 
capillary column (DB-624, 60 m l., 0.25 mm i.d., 1.4 μm film 
thickness, Agilent Technologies). Helium 5.6 IP (SOL Group, Italy) 
was used as carrier gas. The experimental conditions used for the 
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thermal desorption, gas chromatographic and mass spectrometric 
methods are given in Table 3.2. 
Table 3.2 Thermal desorption, gas chromatographic and mass 
spectrometric methods. 
MTD 1 
Thermal desorption method 
Valve and transfer line Temperature  170 °C 
Tube desorption Temperature 250 °C 
Tube desorption Time 5 min 
Tube desorption Pressure 90 kPa 
Trap focusing Temperature 5 °C 
Trap desorption Temperature 250 °C 
Trap desorption Time 30 min 
Gas chromatographic method 
Inlet Temperature 200 °C 
Oven temperature ramps 
35 °C for 10 min; 
4 °C/min until 130 °C for 2 min; 
25 °C/min until 260 °C for 15 min 
Column head Pressure 210 kPa 
Inlet mode split 
Split flow 10 mL/min 
Transfer line temperature 260 °C 
Mass spectrometric method 
Ion source temperature 250 °C 
Scan mode Full Scan 18-200 amu and SIM 
Scan rate 813.1 amu/sec Dwell Time 50 ms for each ion 
 
In Table 3.3 are shown the ions of the compounds that were 
identified by MS operating in selected ion mode (SIM). 
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Table 3.3 Characteristic ions in SIM mass spectra used in MTD 1. 
Segment Compound SIM Mass Retention Time (min) 
0 – 8.40 
Pentane 43 6.89 
Ethanol 45 7.19 
Sevoflurane 131 7.35 
Isoprene 67 7.64 
8.40 – 10.10 
Acetone 58 8.48 
Dimethylsulphide 62 8.71 
2-propanol 45 9.14 
Acetonitrile 41 9.50 
10.10 – 14.50 
2-methylpentane 71 10.49 
Hexane 57 12.69 
1-propanol 31 13.75 
14.50 – 20.00 
2,3-butanedione 43 15.11 
Ethyl acetate 43 15.91 
Chloroform 83 16.72 
Carbontetrachloride 119 18.03 
Benzene 78 18.79 
20.00 – 24.20 
1-butanol 56 21.22 
Trichloroethylene 95 21.29 
2-pentanone 43 22.01 
Hexafluoroisopropanol 99 23.43 
24.20 – 27.00 
Dimethyldisulphide 94 25.07 
3-hydroxy-2-butanone 43 25.15 
Toluene-D8 98 25.87 
Toluene 91 26.12 
27.00 – 35.00 
Tetrachloroethylene 166 28.19 
4-heptanone 43 33.23 
35.00 – 56.00 m-cresol 108 41.83 
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3.6 Optimization of HPLC assay for uremic toxins 
determination 
 
The determination of the absorption spectra of urea, uric acid, 
creatinine and β2-microglobulin and fluorescence spectrum of β2-
microglobulin allowed to select the best wavelengths for HPLC and 
flow injection analyses. 
Figure 3.4 shows the absorption spectra of these four uremic 
toxins in the range 200 – 600 nm measured in standard solutions 
at a concentration of 8.3 mM, 11.9, 5.3 and 8.6 μM respectively. 
Figure 3.5, on the other hand, shows the fluorescence spectrum of 
β2-microglobulin (excitation wavelength 220 nm) in the range 230 – 
510 nm obtained by using a standard solution of β2-microglobulin 
at a concentration of 0.17 μM. 
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Figure 3.4 Absorption spectra of urea (red line), uric acid (black line), 
creatinine (magenta line) and β2-microglobulin (blue line). 
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Figure 3.5 Fluorescence spectrum of β2-microglobulin. 
From these spectra, three wavelengths for UV absorption (235, 292 
and 280 nm) and a pair of wavelengths for spectrofluorimetric 
measurements (excitation wavelength 220 nm, emission 
wavelength 340 nm) were selected. 
As it can be seen in Figure 3.4, urea do not shown light absorption 
in the range 200 – 600 nm, so it does not contribute to the UV 
signal. 
The flow-injection measurements were carried out by the Jasco 
HPLC system using milliQ water at a flow rate of 1 mL/min. The 
injection volume was 25 μL and the total run time was 2 minutes. 
Chromatographic separations by the Jasco HPLC system were 
carried out in isocratic conditions with a XTerra MS-C18 column 
(Waters, 250 x 4.6 mm, 2.5 µm). A mobile phase containing 98% of 
a 1% formic acid solution in water and 2% acetonitrile and was 
used at a flow rate of 1 mL/min at 25 °C. The injection volume was 
25 μL. 
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CHAPTER 4 
 
 
Experimental section 
 
 
4.1 Samples collection and preparation 
 
The quality of information in any analytical investigation is closely 
linked to the ability to obtain representative and homogeneous 
samples and to ensure the minimum possible alteration of the 
chemical composition of the sample during storage, pre-treatment 
and analysis. The manipulations required by the analytical 
procedure and the contact with the various materials used are 
definitely the most important aspects. In view of this premise, 
particular attention was paid to issues regarding oral fluid, sweat, 
breath and spent dialysate sampling and sample treatment. 
 
4.1.1 Oral fluid 
4.1.1.1 Sample collection device 
 
Three different devices from Salivette (Salivette®, Sarstedt, 
Germany), namely a cotton swab, a cotton swab impregnated with 
citric acid and a polyester swab, were compared to evaluate the 
release of interfering compounds from the swab materials and the 
sample recovery. 
An aliquot (2 mL) of a standard working solution with a warfarin 
concentration of 10 ng/mL was absorbed into the three swabs and 
recovered by centrifugation at 3000 rpm for 5 min. An aliquot (25 
Experimental section 
 
 88
μL) of each sample was then analyzed by HPLC with fluorescence 
detection. 
The chromatographic separation was carried out in isocratic 
conditions by the Chromspher 5 PAH column with a 72% PBS and 
28% methanol mobile phase at a flow rate of 1.0 mL/min, injection 
volume 25 μL, temperature 25°C. 
The recovery percentage was calculated from the ratio between the 
average warfarin concentration in the samples recovered from the 
swab and the initial concentration. 
The results summarized in Figure 4.1 and Table 4.1 show that the 
polyester swab was the device more suitable for oral fluid sampling 
for the lowest background contamination and the highest recovery 
percentage. 
 
Figure 4.1 HPLC chromatograms of a standard working solution 
containing 10 ng/mL of warfarin (black line) and of the 
solutions recovered by the three different swabs: cotton (red 
line), cotton + citric acid (green line) and polyester (blue line). 
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Table 4.1 Sample recovery percentages from the different swabs. 
Swab Average recovery % (CV %) 
Cotton 88 % (10 %) 
Cotton + citric acid 62 % (3 %) 
Polyester 98 % (1 %) 
Therefore, the collection of oral fluid samples was carried out by 
roll-shaped biocompatible polyester swabs (Salivette®, Sarstedt) 
which were delivered to the study subjects to be kept in the mouth 
for 5 minutes. Oral fluid was then recovered by centrifugation of 
the swabs at 3000 rpm for 5 minutes. 
All samples were collected at the same time (8.30 - 10.00 AM) to 
avoid any effects due to possible circadian variations. Patients 
generally take warfarin in the late afternoon, therefore it can be 
assumed that the last dose had been completely absorbed when 
samples were collected. 
 
4.1.1.2 Sample storage 
 
According to the medical literature, oral fluid specimens should 
preferably be kept refrigerated after collection to maintain sample 
integrity; this prevents the degradation of some molecules in oral 
fluid and the bacterial growth. In the present work, oral fluid 
samples were stored in 1.5 mL polypropylene tubes (Safe-Lock, 
Eppendorf) at room temperature when analysis was carried out 
within 90 minutes from collection, otherwise at 4 °C in the 
refrigerator. 
The stability of the treated samples (i.e. centrifuged and filtrated) 
during a one and half month storage at 4 °C was assessed in 
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aliquots of a pooled patient oral fluid sample (POFS) obtained by 
pooling samples from 20 patients (Table 4.2 and Figure 4.2). 
The accuracy of the initial warfarin concentration estimate in the 
POFS (2.9 ng/mL) was confirmed by calculating the average 
warfarin concentration in the 20 oral fluid samples composing the 
POFS (2.8 ng/mL). The difference between these two values was 
not statistically significant (p <0.05). 
Table 4.2 Time stability of a POFS stored at 4 °C. 
Time (days) 0 7 14 21 28 42 
Average warfarin 
concentration [ng/mL] 2.9 2.8 3.2 2.6 2.9 2.6 
SD (n=3) 0.03 0.01 0.04 0.06 0.02 0.09 
Relative error % -- -1.3 10.3 -8.3 1.2 -10.3 
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Figure 4.2 Time stability of a POFS stored at 4 °C. 
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These results allowed to state that no significant degradation 
occurred in oral fluid sample stored in 1.5 mL polypropylene tubes 
at 4 °C within the considered time span. 
 
4.1.1.3 Sample preparation 
 
The analysis of biological samples generally requires a preliminary 
stage to obtain the analyte in the appropriate form for the 
analytical determination. In oral fluid, for example, albumin and 
other proteins could potentially form stable complexes with 
warfarin, thereby reducing the free fraction of analyte. To exclude 
this possibility, two procedures were compared with the simple oral 
fluid filtration by 0.2 μm regenerated cellulose syringe filters 
(Spartan, Whatman). The first procedure (extraction of warfarin 
from oral fluid samples) consisted in the addition of sulphuric acid 
followed by a liquid/liquid extraction with organic solvents, the 
second (ultrafiltration of oral fluid samples) consisted in the 
ultrafiltration by centrifugal filters with a cutoff at a molecular 
weight of 3000 Da, which prevent any complex with albumin 
(60000 Da) to pass into solution. 
The three procedures were compared in terms of percentage of 
recovery, time and costs. All measurement were performed in 
triplicate using aliquots of the same POFS. 
 
4.1.1.3.1 Extraction of warfarin from oral fluid 
samples 
 
Aliquots (1 mL) of POFS were spiked with 2 mL of 0.5 M sulphuric 
acid and 500 μL of ethanol. The addition of sulphuric acid 
dissociates any warfarin/protein complex, allowing to measure the 
total warfarin concentration, whereas ethanol prevents the 
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formation of emulsions. The resulting solution was added with 4 
mL of a 1:5 dichloromethane/hexane mixture for the extraction of 
warfarin and then stirred for 15 minutes and centrifuged for 5 
minutes at 3000 rpm. Freezing the solution at -80 °C facilitated the 
separation of the two phases. The upper organic phase was 
transferred into a clean vial and evaporated under vacuum. The 
residue was then reconstituted with 1 mL of PBS and analyzed by 
HPLC with fluorescence detection. 
 
4.1.1.3.2 Ultrafiltration of oral fluid samples 
 
Aliquots (1 mL) of POFS were transferred into Amicon tubes 
(Amicon® Ultra-4, Millipore) with a molecular weight cutoff of 3000 
Da and ultrafiltered by centrifugation at 4000 rcf for 40 minutes at 
20 °C. The ultrafiltrate was so ready for analysis. 
Table 4.3 Average percentage sample recovery (n = 3) for the different 
pre-treatment procedures. 
Sample pre-treatment Average recovery % (CV %) Time and costs 
Extraction 89 % (4 %) medium 
Ultrafiltration 93 % (2 %) high 
Filtration 99 % (1 %) low 
The results obtained, summarized in Table 4.3, allowed to 
conclude that simple filtration was the best procedure in terms of 
quantitative recovery of the analyte, time and costs. 
 
4.1.1.3.3 pH measurement of oral fluid samples 
 
Before starting the clinical study, the possibility of measuring pH 
of the oral fluid samples was evaluated since warfarin is a weak 
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acid (pKa = 5.19 at 25 °C) and the drug transfer from plasma to 
oral fluid can be influenced by this parameter [27]. 
pH paper strips (Pehanon, Macherey Nagel) having a 0.3 (pH) unit 
resolution in the range 5.2 to 8.1 were used to measure the pH of 
patients’ oral fluid samples during the clinical study. 
Since about two hours elapsed between sample collection and the 
analysis, the stability of the pH value during this time span had to 
be tested. pH values of several patient oral fluid samples were 
measured in the same day immediately after collection (1), after 
centrifugation of the sampling device (2), after filtration of the 
sample (3) and at two hours from collection (4). 
Table 4.4 shows a typical result highlighting that no significant 
changes occurred in the pH of oral fluid samples during sample 
recovery and treatment as well as at two hours from collection. 
Table 4.4 Oral fluid pH value during the various stages of the 
methodology. 
Stage Oral fluid pH 
1 6.6 
2 6.7 
3 6.6 
4 6.7 
 
4.1.2 Sweat 
 
Sweat stimulation and collection was carried out according to 
methods reported in literature for the diagnosis of cystic fibrosis 
[249, 250]. Pilocarpine was delivered through the skin in the 
forearm region via iontophoresis (2 mA for 5 minutes), and then 
the skin was rinsed with water and dried with paper. A paper filter 
(Whatman n.42, 55 mm), previously put in a plastic canister and 
weighed, was applied onto the stimulated region and hold in place 
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by wrapping the forearm with a plastic film. After 30 minutes, 
paper was removed and weighed again, sweat was then eluted from 
the filter by adding 9 mL of PBS. An extraction procedure was set 
up to lower the level of sweat dilution; 200 μL of concentrated 
sulphuric acid and then 9 mL of 1:5 dichloromethane/hexane 
mixture were added to the sample. After centrifugation at 3000 
rpm for 5 min, the upper organic phase was transferred into a 
clean vial and evaporated under vacuum. The residue was then 
reconstituted in 1 mL of PBS and stored at 4 °C until assay. 
 
4.1.3 Breath 
 
The analytical methodology used for collection and pretreatment of 
breath samples was developed in previous work [251, 252]. 
The sampling procedure was optimized by comparing three 
different bag materials such as Nalophan, Tedlar and Cali-5-bonds. 
The comparison between these materials was carried out by testing 
the release of interfering compounds and the chemical stability of 
accurately prepared gas mixtures containing many compounds of 
interest at known concentration. Nalophan, due to low background 
contamination and cost that enables the preparation of ready-to-
use disposable bags, was the most suitable material for breath 
collection. 
The breath sampling system consisted of a disposable mouthpiece, 
a non-return valve, a Nalophan bag and a Teflon tube (Figure 4.3). 
The Teflon tube allowed the connection of the bag to the adsorption 
tube for transferring the breath sample. The mouthpiece, the non-
return valve and connections were sterilized by low-temperature, 
hydrogen peroxide gas plasma technology. 
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Figure 4.3 Breath sampling system: A) disposable mouthpiece; B) non-
return valve; C) Nalophan bag; D) Teflon tube. 
Nalophan bags were home made from a 20 μm thick roll of 
Nalophan tube, (Tillmanns S.p.a., Milan, Italy). To make a 
sampling bag, a 50 cm portion was cut from the roll. One end was 
wrapped, folded and tightened by nylon cable ties, the other one 
was wrapped and tightened around a Teflon tube (1/4 inch i.d.) 
connected to a valve. 
Due to the low concentration in breath of most volatile organic 
compounds (VOCs), we pre-concentrated the collected sample 
before the analysis by flowing a fixed volume of sample into an 
adsorption tube filled with a suitable stationary phase (solid phase 
extraction, SPE). 
The choice of the stationary phase was carried out by evaluating 
the performances of two different adsorption tubes, one packed 
with Tenax GR and the other (multi-bed adsorption tube) with 
Carbopack Y - Carbopack B – Carboxen 1003. 
Due to the high content of water vapour in the breath, which could 
decrease the retention of analytes in the adsorption tube, the tests 
were carried out by introducing in the pre-concentration system a 
cartridge containing a drying agent. In particular, we tested the 
B 
A 
C 
D 
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effectiveness of anhydrous sodium sulphate, magnesium 
perchlorate and anhydrous calcium sulphate. 
Tenax GR, characterized by a high breakthrough volume for most 
volatile organic compounds and a low affinity for water, and 
sodium sulphate were, respectively, the stationary phase and the 
drying agent most suitable for our purpose. 
On the basis of previous studies, sampling bags were stabilized at 
37 °C for half an hour to prevent water condensation on the bag 
walls, then a known volume of sample was sucked through a 
drying tube filled with 9 g of anhydrous sodium sulphate (SKC, 
Italy) for water removal and a glass thermal desorption tube pre-
packed with 250 mg of 60/80 mesh Tenax GR phase (70% Tenax 
TA, 2,6-diphenyl-p-phenylene oxide and 30% graphite, Supelco, 
Sigma-Aldrich, Italy) by a pocket pump. The flow was set up on the 
pocket pump and controlled by a flow meter. During the sample 
transfer, the sampling bag and the drying tube were kept at 37 °C, 
whereas the adsorption tube was at ambient temperature (Figure 
4.4). 
 
Figure 4.4 Schematic diagram of sample transfer in the adsorption tube. 
Thermostat 37°C
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4.1.4 Spent dialysate 
 
Spent dialysate samples were collected 10, 30, 60, 120, 180 and 
240 min respectively after the beginning of the dialysis session and 
analyzed by flow-injection. Aliquots of each sample were stored at -
20 °C in polypropylene tubes (Safe-Lock, Eppendorf) for further 
analyses by HPLC. Blood samples were collected before the patient 
was connected to the dialysis machine and 60, 120 and 240 min 
after the beginning of the dialysis treatment. 
 
4.2 Method validation for oral fluid samples 
analysis 
 
The method validation included the evaluation of interferences, 
matrix effect, calibration curve, limit of detection and quantitation, 
intra-day and inter-day precision, stability and recovery. 
 
4.2.1 Interferences 
 
The possible presence of interfering endogenous substances was 
investigated by comparing the warfarin concentration determined 
in a standard working solution containing 5.0 ng/mL, a standard 
oral fluid sample (SOFS) with a spiked concentration of 5.0 ng/mL 
and two patient oral fluid samples (POFSs) with unknown 
concentrations. The samples were analyzed in triplicate, by HPLC-
Fluorimetry with both columns (i.e. Chromspher 5 PAH and 
Poroshell 120 EC-C18) and by HPLC-MS/MS with the column 
Chromspher 5 PAH. Table 4.5 shows the warfarin mean 
concentration and the coefficient of variation for all the samples. 
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Table 4.5 Comparative determination of warfarin in a standard solution, 
SOFS and POFS by HPLC-Fluorimetry with both columns 
(Chromspher 5 PAH and Poroshell 120 EC-C18) and by HPLC-
MS/MS. 
Sample 
Warfarin mean concentration [ng/mL], (n=3) (CV%) 
Expected 
value 
HPLC-Fluo 
(Poroshell) 
HPLC-Fluo 
(Chromspher) 
HPLC-
MS/MS 
Standard 
solution 5.0 4.6 (5%) 4.9 (3%) 5.2 (3%) 
SOFS 5.0 5.3 (6%) 5.0 (4%) 4.9 (4%) 
POFS-1 unknown 3.5 (6%) 4.5 (5%) 3.2 (7%) 
POFS-2 unknown 7.1 (4%) 11.1 (4%) 6.3 (6%) 
These results highlighted a very good agreement between the 
various methods in the case of the standard solution and the 
SOFS, both with an expected value of 5.0 ng/mL. The difference 
between the concentrations measured with HPLC-MS/MS and 
HPLC-Fluorimetry was about 10%. 
The situation was quite different for the two samples collected from 
patients under oral anticoagulant therapy. The concentration 
values obtained by the HPLC-MS/MS, which were assumed as 
reference values, and by the HPLC-Fluorimetry with Poroshell 120 
EC-C18 were in good agreement (+9% for POFS-1 and + 12% for 
POFS-2), whereas the values obtained by the HPLC-Fluorimetry 
with Chromspher 5 PAH column were much higher (+40% for 
POFS-1 and + 76% for POFS-2). The interference, which was only 
present in the patients’ samples, may result from the presence of a 
warfarin metabolite [253]. On the basis of these results, the 
Poroshell 120 EC-C18 column was used in the subsequent 
evaluations of the performance of the method and in the clinical 
study. 
Figure 4.5 shows the HPLC chromatograms of a warfarin standard 
solution, a COFS, a SOFS and a POFS. The standard solution, the 
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SOFS and the POFS had approximately the same warfarin 
concentrations.  
Chromatographic separation was carried out in isocratic conditions 
by the Poroshell 120 EC-C18 column with a 65% PBS and 35% 
methanol mobile phase at a flow rate of 0.7 mL/min, injection 
volume 25 μL, temperature 25°C and fluorescence detection. 
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Figure 4.5 HPLC chromatograms of: A) a standard working solution with 
a warfarin concentration of 1.5 ng/mL; B) a control oral fluid 
sample (COFS); C) a standard oral fluid sample (SOFS) with a 
warfarin concentration of 1.4 ng/mL; D) a patient oral fluid 
sample (POFS) with a warfarin concentration of 1.4 ng/mL. 
The warfarin peaks had a symmetric shape and were well 
separated from the other chromatographic signals. The retention 
time (tR) was 10.2 min with a standard deviation of 0.1 min in five 
replicate measurements. 
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The same experimental conditions were used for the analysis of 
patients’ sweat. These analyses proved problematic for the 
collection of an insufficient amount of sample in most cases, likely 
due to a diminished capability of sweating at older age [254]. Only 
qualitative information was obtained confirming the presence of the 
drug at concentration levels similar to oral fluid (Figure 4.6). 
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Figure 4.6 HPLC chromatograms of representative sweat samples: A) a 
blank sweat sample from a volunteer not taking the drug; B) a 
patient sweat sample, a warfarin concentration of about 4 
ng/mL was estimated (tr = 10.2 min). 
 
4.2.2 Matrix effect 
 
The evidence that the shape and position of the warfarin peaks 
were not affected by the presence of the oral fluid matrix (Fig. 4.5) 
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suggested the absence of any notable matrix effect. This hypothesis 
was confirmed by comparison of the slopes of the calibration 
curves obtained in the 1-10 ng/mL concentration range for a set of 
standard working solutions and a set of spiked POFSs. The two set 
were prepared as follows: 
- calibration curve with standard working solutions: 20 μL of 
standard working solution with a warfarin concentration 
respectively of 10, 20, 40 and 100 ng/mL were added to 180 
μL of 25 mM PBS (Figure 4.7 black line); 
- calibration curve with spiked POFSs: 20 μL of standard 
working solution with a warfarin concentration respectively of 
10, 20, 40 and 100 ng/mL were added to 180 μL of pooled 
patient oral fluid sample (Figure 4.7 blue line). 
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Figure 4.7 Calibration curves obtained with standard working solutions 
(A, black line) and spiked POFSs (B, blue line). 
Table 4.6 shows a comparison of the parameters of the two 
calibration curves. 
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Table 4.6 Statistical data of warfarin calibration curves. 
Parameter A B 
Equation Y = a X + b Y = a X + b 
Slope 19750 19540 
Standard Error 90 60 
Intercept 0 78390 
Standard Error -- 270 
Coefficient of determination 0.999 0.999 
The limited difference of the slopes of the two calibration curves, 
which were 19750 ± 90 and 19540 ± 60 respectively, confirmed the 
hypothesis that oral fluid matrix does not affect results. The slopes 
values were compared by testing the null hypothesis and their 
difference resulted not significant (P = 1, two-tailed). 
 
4.2.3 Calibration curve 
 
In order to evaluate the working range, standard working solutions 
of warfarin in PBS at concentration levels ranging from 1 to 20 
ng/mL were used as calibrators. These solutions were analyzed in 
triplicate and then fluorescence detector response (i.e. warfarin 
peak area) was plotted against corresponding warfarin 
concentration value (Figure 4.8). 
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Figure 4.8 Typical warfarin calibration curve. 
As it can be seen in Figure 4.8, the warfarin peak area linearly 
increased with the warfarin concentration of standard working 
solutions in the observed concentration range. 
According to a linear regression analysis, the best fit model was: 
y=(19550 ± 60) x, R2=0.999 (Table 4.7). 
Table 4.7 Statistical data of warfarin calibration curve. 
Parameter Value 
Equation Y = a X + b 
Slope 19550 
Standard Error 60 
Intercept 0 
Standard Error -- 
Coefficient of determination 0.999 
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4.2.4 Limit of detection and quantitation 
 
In order to assess limit of detection (LOD) and limit of quantitation 
(LOQ), a SOFS at about 0.5 ng/mL was prepared and assumed as 
“blank” or the closest concentration to the limit of detection. This 
sample was analyzed five times and the corresponding results are 
shown in Table 4.8. According to the IUPAC definition [255], the 
LOD was evaluated as three times the standard deviation sb of the 
“blank”, which corresponds to about 0.2 ng/mL, whereas the LOQ 
as ten times the standard deviation sb of the “blank”, which 
corresponds to about 0.8 ng/mL. 
Table 4.8 Statistical data of five replicate measurements of a SOFS 
sample. 
RUN Warfarin concentration [ng/mL] 
1 0.4 
2 0.6 
3 0.4 
4 0.5 
5 0.5 
Average [ng/mL] 0.5 
sb [ng/mL] 0.1 
 
4.2.5 Precision and accuracy 
 
Intra-day and inter-day precision and accuracy assessment was 
conducted at three different concentration levels of standard 
working solutions, 1, 5 and 20 ng/mL, with three determinations 
per concentration and per day. 
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Table 4.9 Precision and accuracy of standard working solutions (n=3). 
 Nominal concentration [ng/mL] 
 1.00 5.20 20.5 
Day Average CV % Average CV % Average CV % 
1 1.00 0.6 5.01 1.6 19.8 0.8 
2 1.03 4.7 5.12 0.4 20.1 1.2 
3 0.92 2.4 5.20 0.8 20.6 0.8 
Average 0.98 5.11 20.2 
CV % 5.8 1.9 2.0 
Relative 
Error % -2.0 -1.7 -1.4 
Table 4.9 shows that the precision or within-run repeatability did 
not exceed 5 % at low concentration level and 2 % at medium and 
high concentration levels and that the inter-day accuracy was 
within 2 % of the actual value at each concentration. 
The quality control procedure for INR measurements consisted in 
analysing three reference samples (normal, low and high INR 
levels) provided by the Instrumentation Laboratory at least once 
every eight hours. A coefficient of variation <1% for measurements 
performed on the same day and <3% for measurements performed 
on different days demonstrated the good repeatability of the 
method. 
 
4.2.6 Quality control of analytical data 
 
The quality control of data over time was assessed by 
systematically measuring a standard solution with known content 
of warfarin (5 ng/mL) and comparing the data obtained with the 
expected value. The use of a standard solution of warfarin was 
suggested by its stability, homogeneity and availability in sufficient 
quantity to repeat the analysis over time. 
Experimental section 
 
 106
Therefore, multiple measurements of the standard solution were 
included within all the sequences of analyses of patients’ samples. 
These data made it possible to draw a control chart (Figure 4.9) 
reporting the daily average values of the ratio between warfarin 
peak area and concentration (purple dots), the average of all the 
ratios obtained during the experimental campaign (purple dashed 
line), the attention limits (average ± SD, magenta line) and the 
control limits (average ± 2SD, blue line). 
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Figure 4.9  Warfarin control chart. 
As it can be seen from the control chart, in about four months of 
experimental activity, the control limit was never exceeded, 
indicating very good control of experimental conditions. 
 
4.2.7 Effect of pH on warfarin recovery 
 
The recovery percentage of warfarin from the sampling swabs was 
estimated at three levels of pH (5.2, 6, 6.9 and 7.5) covering the 
range of variability observed in the oral fluid samples. Four SOFSs 
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with a warfarin concentration of about 5 ng/mL, a volume of 4mL 
and an initial pH value of 6.9 were used for the experiments. Two 
of them were acidified to pH 5.2 and 6 by adding 20 µL and 10 µL 
of phosphoric acid 1 M respectively, another was alkalinized to pH 
7.5 by adding 8 μL of sodium hydroxide 1 M. Each of these four 
samples was divided into four aliquots. The first aliquot was 
analyzed without any further treatment, the other three were 
absorbed into the synthetic swabs and treated as normal samples. 
The recovery percentage was then calculated from the ratio 
between the average warfarin concentration in the samples 
recovered from the swab and the initial concentration. 
The recovery of warfarin from the sampling swabs was generally 
satisfactory. A slight dependence on pH was found, with recovery 
percentages equal to 93 ± 0.2 % at pH 5.2, 99 ± 0.1 % at pH 6.0 
and 100 ± 0.1 % at pH 6.9 and 7.5 (Table 4.10). 
Table 4.10 Sample recovery percentage from the swab at four levels of pH. 
pH Average recovery % (CV %) 
5.2 93 % (0.2 %) 
6.0 99 % (0.1 %) 
6.9 100 % (0.1 %) 
7.5 100 % (0.1 %) 
Only a very limited fraction of patients (4 %) showed a pH value of 
the oral fluid lower than 6.0, so the slightly different recovery 
percentage was considered negligible. In a few trials carried out 
with acidic oral fluid samples, the small fraction of warfarin 
remaining in the sampling swab was recovered by changing the 
sample pH to about 7.0 by the addition of 50 - 100 µL of PBS 1 M, 
reabsorbing the sample in the sampling swab and centrifuging the 
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swab a second time. Thus, recovery percentages obtained were 
almost quantitative. 
 
4.3 Method validation for breath samples analysis 
4.3.1 Determination of the response factors for the 
quantification of compounds 
 
Instrumental responses may change over time, so quantification by 
the simple comparison of peak areas it is not always the best 
practice. Thus, the determination of the instrument response factor 
relative to an internal standard of each compounds becomes 
necessary to achieve a reasonable level of accuracy. 
Since breath is a gaseous matrix, a gaseous standard mixture was 
prepared to calculate a response factor (K) and determine the 
concentration of the compounds of interest. 
Adsorption tubes were loaded with MIX 25 and a labelled internal 
gaseous standard mixture, composed of Toluene-D8 and 
Isopropanol-D8 (MIX 2D). The response factor for each compound 
was calculated with reference to the labelled compounds according 
to the following relation: 
iD
Di
mA
mA
K ⋅
⋅=
8
8  (4.1) 
where Ai and mi are the chromatographic peak areas (a.u.) and the 
theoretical amounts (ng loaded in the desorption tube) of the ith- 
compound, AD8 and mD8 are the chromatographic peak areas (a.u.) 
and the theoretical amounts (ng loaded in the desorption tube) of 
the internal labelled standard (toluene-D8). 
Ai and AD8 were obtained by injecting 250 µL of MIX 25 and 50 µL 
of MIX 2D through a septum into the aspiration flow, during pre-
concentration of 250 mL of pure air in the adsorption tube. 
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The concentrations of compounds were calculated as follows: 
VKA
mA
C
D
Di
i
1
8
8 ⋅⋅
⋅=  (4.2) 
where Ai is the chromatographic peak area of generic compound 
(a.u.), AD8 and mD8 are the chromatographic peak areas (a.u.) and 
the theoretical amount (ng loaded in the desorption tube) of 
internal standard (toluene-D8), K is the response factor and V is 
the sampled volume (L). 
The average response factors for the components of MIX 25 and the 
corresponding coefficients of variation are reported in Table 4.11. 
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Table 4.11 Response factors of the compounds in MIX 25. 
Analytes Response factor (K) CV % 
Pentane 0.11 3% 
Ethanol 0.09 6% 
Isoprene 0.07 6% 
Acetone 0.11 3% 
Dimethylsulphide 0.05 5% 
2-propanol 0.51 7% 
Acetonitrile 0.34 3% 
2-methylpentane 0.12 6% 
Hexane 0.30 3% 
1-propanol 0.17 5% 
2,3-butanedione 0.34 5% 
Ethyl acetate 0.43 4% 
Chloroform 0.62 5% 
Carbontetrachloride 0.71 6% 
Benzene 1.54 1% 
1-butanol 0.16 4% 
Trichloroethylene 0.39 4% 
2-pentanone 0.93 5% 
Hexafluoroisopropanol 0.54 7% 
Dimethyldisulphide 0.61 5% 
3-hydroxy-2-butanone 0.03 6% 
Toluene 1.26 2% 
Tetrachloroethylene 0.68 6% 
4-heptanone 1.06 6% 
m-cresol 0.16 29% 
 
4.3.2 Linearity of sevoflurane 
 
The range of linearity for sevoflurane was assessed for the response 
of the mass spectrometer detector and for the breakthrough 
volume on Tenax GR adsorption tube. Two gaseous samples of 
sevoflurane were prepared. The first was prepared by injecting 5 μL 
of liquid sevoflurane in a pre-evacuated 2 L glass flask equipped 
with a septum, the second by injecting 5 μL of liquid sevoflurane in 
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the flow of pure air during the filling of a 10 L Nalophan bag. Glass 
flask and Nalophan bag were kept at 37 °C. 
To evaluate linearity of mass spectrometry detector response, 
increasing volumes (10, 20 and 50 μL, triplicate samples) were 
drawn from the glass flask, directly injected into the GC-MS and 
analyzed according to the methods reported in Table 3.2. 
Figure 4.10 shows the sevoflurane average peak area versus the 
injected volume. 
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Figure 4.10Calibration curve of gaseous sevoflurane directly injected into 
the GC-MS. 
Increasing volumes (10, 20 and 50 mL) of sample drawn from the 
bag were transferred into the adsorption tubes by a pocket pump 
(flow 10 mL/min) to evaluate the sevoflurane breakthrough volume 
for Tenax GR adsorption tubes. The tubes were analyzed according 
to the methods reported in Table 3.2. 
Figure 4.11 shows the sevoflurane average peak area versus the 
volume of sample pre-concentrated in the adsorption tube. 
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Figure 4.11 Linearity of sevoflurane peak area versus the volume of the 
sample pre-concentrated in Tenax GR adsorption tube. 
From the figures above, it can be seen that sevoflurane has a good 
linearity both in terms of response of mass spectrometry detector 
(R2 = 0.999) and breakthrough volume on Tenax GR adsorption 
tube (R2 = 0.997) in the range considered. 
 
4.3.3 Time stability of sevoflurane concentration in 
the Nalophan bag 
 
A gaseous sample of sevoflurane was used to evaluate the stability 
of the concentration of this gas in the Nalophan bag. A volume (5 
μL) of liquid sevoflurane was injected in the flow of pure air during 
the filling of a 2 L Nalophan bag. The sevoflurane concentration in 
the bag was 477 ppmv. 
To simplify the experimental procedure, triplicate direct injections 
of 50 μL of bag sample into the GC-MS were performed soon after 
filling (Time 0) and after 0.5, 2.5, 5 and 24 hours. 
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Figure 4.12 shows the sevoflurane average peak area (normalized 
with respect to the peak area at time zero) as a function of the 
storage time in the bag. 
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Figure 4.12Time stability of sevoflurane sample in the Nalophan bag. 
The sevoflurane concentration in the Nalophan bag was stable 
within 6 hours and had a 10 % decrease within 24 hours. 
 
4.4 Method validation for the analysis of spent 
dialysate samples 
4.4.1 Calibration curves 
 
Standard working solutions of uric acid, creatinine and β2-
microglobulin were used to calibrate the HPLC system in the 
concentration range of 2-50, 0.6-60 and 2-25 μg/mL respectively. 
Such ranges include the concentration ranges observed in 
dialysate samples, which are 2-33, 0.8-47 and 0.5-7.3 μg/mL for 
uric acid, creatinine and β2-microglobulin respectively. The UV 
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absorbances of the uric acid, creatinine and β2-microglobulin 
solutions were measured in triplicate at 292, 235 and 280 nm 
respectively, whereas the fluorescence emission of the β2-
microglobulin solution was measured at 340 nm (excitation 
wavelength 220 nm). 
The detector signal (i.e. peak area) obtained by flow-injection was 
then plotted against the corresponding concentration value 
(Figures 4.13 – 4.15). 
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Figure 4.13Calibration curve of uric acid at 292 nm. 
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Figure 4.14 Calibration curve of creatinine at 235 nm. 
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Figure 4.15 Calibration curve of β2-microglobulin at 280 nm (a) and 220-
340 nm (b). 
The uric acid peak area linearly increased with concentration in 
the range 2 – 50 μg/mL. According to a linear regression analysis, 
the best fit model was: y = (112000 ± 400) x, R2 = 0.999. The 
creatinine peak area linearly increased with concentration in the 
range 0.6 – 60 μg/mL. According to a linear regression analysis, 
the best fit model was: y = (60000 ± 2000) x, R2 = 0.997. The β2-
microglobulin peak area increased with concentration in the range 
2 – 25 μg/mL. According to a linear regression analysis, the best fit 
model for UV was: y = (1690 ± 10) x, R2 = 0.998, whereas according 
to a polynomial regression analysis, the best fit model for 
fluorescence was y = (220 ± 10) x2 + (500 ± 200) x, R2 = 0.999. 
 
Due to the relevance of its contribution to UV absorbance (Table 
5.5), a particular attention was paid to the uric acid.  
The HPLC system was also calibrated by spiking a pooled dialysate 
sample (obtained by pooling aliquots (100 μL) of each patient 
sample collected 240 minutes after the beginning of the dialysis 
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treatment) with standard working solutions. The slopes of the two 
calibration curves (i.e. in standard working solutions and in 
dialysate samples) were compared to exclude the presence of 
possible matrix effect. The second curve was then used to measure 
the concentration of uric acid in samples collected from eight 
patients 10 and 240 minutes after the hemodialysis beginning. 
These results were compared to the result obtained by biochemical 
methods (Table 4.12). 
The calibration curve in spent dialysate was obtained by adding 50 
μL of standard working solutions with uric acid concentrations of 
50, 100, 150 and 300 μg/mL respectively to 450 μL aliquots of the 
pooled dialysate reference sample. 
The chromatographic separation was carried out in isocratic 
conditions by a XTerra MS-C18 column thermostated at 25 °C. The 
mobile phase consisted of 98% of a 1% formic acid solution in 
water and 2% acetonitrile. The flow rate and the injection volume 
were 1 mL/min and 25 μL respectively. All HPLC measurements 
were carried out by setting the spectrophotometric detector at an 
absorption wavelength of 292 nm. 
Figure 4.16 shows chromatographic peaks relevant to uric acid in 
the spent dialysate reference sample (A) (retention time = 4.18 
min). 
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Figure 4.16 Chromatographic peaks of uric acid in the spent dialysate 
reference sample as it is (black line) and after addition of 
different amounts of uric acid: 5 (red line), 10 (blue line), 15 
(magenta line) and 30 (green line) μg/mL. 
According to a linear regression analysis, the best fit model for uric 
acid in the reference dialysate sample was: y = (86300 ± 700) x + 
(440000 ± 12000), R2 = 0.999. The slope of the curve was 
compared to the one obtained in standard working solutions 
(87700 ± 300) by testing the null hypothesis and their difference 
resulted not significant (P = 0.80, two-tailed). 
Obtaining the same shape and position of the uric acid peaks in 
standard working solutions and spiked reference sample, and the 
same slope of the calibration curve too, made us exclude the 
presence of any notable matrix effect. 
The equation of calibration curve in spent dialysate was used to 
calculate the uric acid concentration in the samples collected from 
eight patients 10 and 240 minutes after the hemodialysis 
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beginning (Table 4.12). A good agreement was found with values 
obtained by biochemical methods.  
Table 4.12  Comparison between uric acid concentration measured in 
spent dialysate samples by biochemical methods (A) and by 
HPLC (B). 
Samples A B Percent error (%) 
t 
= 
10
 m
in
 
P1 22 23 -2 
P2 22 23 -3 
P3 12 11 -6 
P4 4 4 3 
P5 15 14 -6 
P6 23 23 -1 
P7 19 19 -3 
P8 7 7 2 
t 
= 
24
0 
m
in
 
P1 6 6 7 
P2 11 11 -1 
P3 5 5 7 
P4 2 2 -9 
P5 6 6 5 
P6 7 7 7 
P7 4 4 -8 
P8 3 3 0.2 
 
The maximum percentage deviation for all the samples was less 
than 10 % and one-way analysis of variance calculated a 
probability higher than 98% for the two datasets not to be 
significantly different. Such agreement proved that the HPLC 
system was correctly calibrated and indirectly confirmed the 
accuracy of the estimates of the average percentage contribution of 
uric acid to the overall signal (paragraph 5.4).  
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CHAPTER 5 
 
 
Clinical applications: results and 
discussion 
 
 
5.1 Monitoring of warfarin therapy 
 
The study on oral anticoagulants was approved by the Ethics 
Committee of the Azienda Ospedaliero Universitaria Pisana (AOUP) 
with the deliberation n° 2592. The analytical methodology 
described in chapter 3 and 4 was used for a clinical study involving 
50 patients undergoing oral anticoagulant therapy with 
Coumadin®, whose active principle is Warfarin sodium, and ten 
nominally healthy subjects, for non invasive monitoring of the 
warfarin in oral fluid. 
All patients and nominally healthy volunteers were accepted in the 
study after receiving oral and written information and signing a 
written informed consent. The enrolment and sampling were 
carried out at a local anticoagulation clinic (Surveillance centre for 
oral anticoagulant therapy-AOUP). Both activities were performed 
while patients were waiting for the periodic check of the degree of 
anticoagulation of their blood. The collection of oral fluid samples 
was carried out  in the morning (from 8:30 to 10:00 or so) to avoid 
any effect due to possible circadian variations. 
Fifty adults (27 males, 23 females) patients on warfarin therapy 
were recruited. Patients with hepatic or kidney pathologies were 
excluded from the study. The enrolled subjects were treated for 
atrial fibrillation (AF, 62%), deep vein thrombosis (DVT, 12%), 
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pulmonary embolism (PE, 10%), as mechanical or biological heart 
valve bearers (MHV, 10%) or for other reasons (6%). Their mean 
age was 74 ± 9 years (range, 42 – 88 years) and they were on an 
average warfarin dose of 27 ± 13 mg/week (range, 5 – 57.5 
mg/week). INR values varied from 1.2 to 3.8, with an average value 
of 2.3 ± 0.6. Approximately three fifths of the patients (31) had INR 
values within the recommended range for anticoagulation (2.0 - 
3.0). The distributions of warfarin doses and INR values among the 
patients are reported in Figures 5.1 and 5.2 respectively. 
The values of INR and the weekly dose of Coumadin assigned to 
each patient were provided by the laboratory of the clinic (Clinical 
chemical laboratory of the Azienda Ospedaliero Universitaria 
Pisana, AOUP). 
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Figure 5.1 Distribution of the warfarin doses in the patients undergoing 
oral anticoagulant therapy. 
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Figure 5.2 Distribution of the INR values in the patients undergoing oral 
anticoagulant therapy. 
The Mann-Witney test did not highlight statistically significant 
gender differences (p < 0.05) for any of the above parameters. 
Ten nominally healthy subjects who were not taking any drug also 
contributed to the study by providing control samples. 
The concentration of warfarin in the oral fluid samples of patients 
enrolled in this study was determined using the calibration curve 
shown in Figure 4.7 (chapter 4). 
The average concentration of warfarin in the oral fluid samples was 
2.5 ± 1.6 ng/mL, with values ranging from 0.8 to 7.6 ng/mL, 
whereas the pH of the oral fluid was 6.7 ± 0.4 in the range 6.0 - 7.5 
(Figure 5.3). 
Clinical applications: results and discussion 
 
 123
5.7 6.0 6.3 6.6 6.9 7.2 7.5 7.8
0
2
4
6
8
10
12
14
16
 
N
um
be
r o
f p
at
ie
nt
s (
n 
= 
50
)
Oral fluid pH  
Figure 5.3 Distributions of the oral fluid pH values in patients 
undergoing oral anticoagulant therapy. 
Principal component analysis, PCA [256, 257], was used to obtain 
an overall view of the internal structure of the data. The principal 
component analysis produces two plots in which similar items are 
located close to one another: the score plot (Figure 5.4 (a)) shows 
the relationships between the objects, and the loadings plot (Figure 
5.4 (b)) shows the correlation between the variables. 
If the two plots are superimposed, the objects characterized by a 
high value of a variable will be located close to this variable. 
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Figure 5.4 Principal component analysis of patient data: score plot (a) 
and loadings plot (b). Legend: pH of the oral fluid (pH), 
warfarin concentration in the oral fluid (WC), warfarin dose 
(Dose), INR. 
The score plot shows that the majority of patients with INR values 
above the recommended range for anticoagulation form a separate 
group in the upper left corner. The positions of the variables in the 
loadings plot suggest that most patients with high INR values are 
taking doses of warfarin and have similar concentrations of 
warfarin in the oral fluid to patients with INR in the recommended 
therapeutic range. The main exception is patient P9, who falls in 
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the upper right corner for taking high doses of warfarin and shows 
very high concentrations of the drug in the oral fluid. The loadings 
plot also suggests the existence of a positive correlation between 
dose and warfarin concentration in the oral fluid as well as a 
negative correlation between INR and pH values. 
Figure 5.5 reports INR (a) and warfarin concentration values in oral 
fluid (b) versus weekly dose. 
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Figure 5.5 INR (a) and warfarin concentration in oral fluid (b) versus 
dose. 
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No correlation was found between INR values and dose (r = -0.03, p 
= 0.85), whereas there was a clear positive correlation between 
warfarin concentration in the oral fluid and dose (r = 0.39, p = 
0.006). 
The first result reflects the wide variability of patient responses to 
the drug observed in over fifty years of clinical use. This variability 
has been ascribed to factors such as gastrointestinal absorption, 
age, renal and hepatic function, lifestyle (in particular diet, alcohol 
consumption, smoking etc.) [258, 259]. The concomitant 
assumption of other drugs can change the fraction of warfarin 
bound to plasma proteins and influence its pharmacokinetics and 
pharmacodynamics. Genetic variability in the cytochrome P450 (for 
specific CYP isoforms) has also been identified as a further key 
factor [260, 261, 262]. 
The correlation between warfarin concentration in oral fluid and 
dosage is also not surprising. Warfarin concentration in oral fluid 
is expected to mirror (if the pH level in the oral fluid is not much 
lower than plasma pH) the concentration of free warfarin in 
plasma, and to be highly correlated to the total warfarin 
concentration in plasma. The ratio between the concentrations of 
bound and unbound warfarin in plasma, in fact, is reported to be 
generally subject to only minor variations (between 0.01 and 0.03), 
with the exception of the concomitant assumption of other drugs 
capable of displacing bound warfarin from albumin [263]. 
Obviously, the degree of correlation between warfarin 
concentration in oral fluid and dosage cannot be higher than the 
correlation existing between warfarin concentration in plasma and 
dosage. A correlation coefficient of r = 0.55 was found by Lombardi 
et al. [264] between total warfarin concentration in plasma and 
weekly dosage, whereas Huang et al. [265] found a correlation 
coefficient of 0.378 between the concentration of free warfarin in 
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plasma and weekly dosage. Our value is compatible with these 
results. 
A correlation was found between the concentration of warfarin in 
the oral fluid and the pH value (r = 0.37, p = 0.009) (Figure 5.6). 
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Figure 5.6 Correlation between concentration of warfarin and pH in oral 
fluid. 
We believe that this correlation may be due to a hindered warfarin 
transfer from plasma when pH values of the oral fluid approach the 
pKa of warfarin (5.19). In fact the lowest warfarin concentration 
levels in oral fluid were observed in the most acidic samples. Two 
patients, with pH values of oral fluid lower than 6, had to be 
excluded from the study because the warfarin concentration in the 
oral fluid was below the quantification limit. 
Figure 5.7 (a) reports the warfarin concentration in oral fluid 
versus INR. No correlation was found between these two 
parameters if all samples were included (r = -0.11, p = 0.43). 
However, if only the samples with pH values equal or higher than 
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7.2 were considered, a correlation between these two parameters 
was observed (r = 0.84, p = 0.004, Figure 5.7 (b)). 
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Figure 5.7 Warfarin concentration in oral fluid versus INR: all the 
samples (a) (samples with a pH level ≥ 7.2 are indicated by 
full dots) and detail of samples with a pH level ≥ 7.2 (b). 
Although the limited number of patients does not enable a firm 
conclusion to be drawn on this point, the result is compatible with 
the hypothesis that there is a good correlation between the free 
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warfarin concentration in plasma and INR, which is only mirrored 
in the oral fluid when its pH value enables the drug to be 
transferred from the blood. 
Huang et al. [265] found a modest but significant correlation 
between free warfarin in plasma and INR (r = 0.207, p = 0.03), as 
did Lombardi et al. [264] who found a similar correlation between 
total warfarin in plasma and INR (r = 0.25, p = 0.079). 
In comparison with these studies, our set of patients showed a 
lower correlation between warfarin concentration in oral fluid and 
INR when the pH of oral fluid was lower than plasma pH, however 
they showed a higher correlation when these pH values were in the 
same range. This suggests that when pH conditions lead to an 
optimal diffusion from blood, the warfarin assayed in the oral fluid 
may reflect the pharmacodynamics more precisely, thus maybe 
overcoming the effect of an unknown confounding factor connected 
to the complex chemical nature of blood. To confirm this second 
hypothesis, we used measured oral fluid pH values to calculate the 
theoretical warfarin concentration values in plasma (cp) by the 
Rasmussen equation [266]. This was possible taking into account 
that the free fraction of oral fluid (fof) is considered practically equal 
to 1, the free fraction in plasma is assumed equal to 1 % (fp = 1 % 
of total) and the plasmatic pH is buffered to the value of 7.40 (7.40 
± 0.05). 
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Figure 5.8 Correlation between calculated concentration of warfarin in 
plasma and INR for patients with an oral fluid pH ≥ 7.2. 
The use of the pH information resulted in an increased correlation 
(r = 0.91, p= 0.0006, Figure 5.8). 
These results suggest for the first time the existence of a pH-
dependent correlation between oral fluid concentrations of warfarin 
and INR. If confirmed in a larger number of cases, this result could 
represent a first step towards the development of non invasive 
“point of care” systems for monitoring patients on anticoagulation 
therapy. Such devices, easily managed by the patients themselves, 
would allow a frequent self-control of the coagulation level. Such 
control would prevent bleeding events in the time span between 
two INR checks, reduce the number of checks at the clinics and 
help the patient in the management of his diet, thus improving the 
quality of life and reducing costs for national health systems. 
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5.2 Monitoring of volatile compounds in human 
breath during oral glucose tolerance test 
 
The possibility of diagnosing diabetes mellitus by volatile 
compounds in exhaled breath is actively investigated by many 
researchers. Several breath metabolites, for example acetone [267, 
268, 269], isoprene [270], ethanol [271] and methyl nitrate [272, 
273], have been investigated for this purpose, however inconsistent 
data have been reported. 
A protocol was defined to test the hypothesis of different breath 
compositions between healthy and diabetics subjects during oral 
glucose tolerance tests (OGTTs). 
Ubiquitous contamination by isopropanol is a major problem for 
breath analysis in hospital environment, as this compound is 
largely used in skin disinfectants. Furthermore, an enzymatic 
equilibrium exists in blood between this compound and acetone 
(Figure 5.9) [274], which is linked to lipolysis and is regulated by 
the concentration ratio of oxidized NAD (NAD+) and reduced NAD 
(NADH). 
 
Figure 5.9 Enzymatic equilibrium between acetone and isopropanol. 
A remarkable isopropanol contamination was identified in an early 
series of measurements by measuring the concentration levels of 
this compound in ambient air (Figure 5.10). Such contamination 
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was directly altering the concentration levels in breath and could 
also indirectly affect breath acetone levels by enzymatic conversion. 
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Figure 5.10 Isopropanol: breath (bars) and ambient air (circles) 
concentrations. 
Breath sampling was carried out in a dedicated isopropanol free 
room during OGT tests and room air was analyzed periodically to 
confirm contamination free status. 
Room air samples were collected by a gas-tight cylindrical glass 
vessel containing a Nalophan bag. A first connector through the 
vessel lid allowed to connect the bag to the outside, whereas a 
second connection allowed to connect a pump sucking the air 
between bag and vessel wall. The decrease of pressure caused by 
the pump allowed to inflate the bag with room air. After collection, 
room air samples were transferred from the bag into the adsorption 
tube and analyzed with the same procedure of breath samples. 
Sixteen subjects undergoing OGTT, 6 males and 10 females aged 
between 35 and 76 years, were enrolled at the Institute of Clinical 
Physiology (CNR, Pisa, Italy). 
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Mixed expired breath samples were collected by asking the 
subjects to blow up a Nalophan bag. Collections were carried out in 
the morning after a 12 hours fasting, just before glucose 
administration (Time 0) and then every 30 minutes, in 
correspondence to the blood drawings for the measurement of 
glycemia. 
Breath and room air samples were treated as described into 
paragraph 4.1.4 and analyzed according to the methods reported 
in Table 3.2. 
Acetone breath and blood glycaemia concentration values over time 
measured in pathological and healthy subjects are reported in 
Figure 5.11. 
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Figure 5.11 Breath acetone concentrations (bars) and blood glycemia 
(dots) during OGTT: pathological subjects (a) and healthy 
subjects (b). 
A steady decrease of acetone concentration following the 
administration of glucose was observed in all subjects. Such 
decrease is likely the effect of glucose assumption, which shifts 
metabolism from lipolysis to glycolysis. Lipolysis, i.e. the 
breakdown of lipids, involves the hydrolysis of triglycerides into 
free fatty acids followed by further degradation into acetyl units by 
beta oxidation. This process produces ketones, so the initial high 
level of acetone is due to the fasting state before test. As glucose is 
delivered, the acetone production is slowed down and the amount 
lost in breath is not replaced, giving rise to a decrease in 
concentration. 
No correlation was found between acetone and glycemia trend 
during OGTT, but the results have shown the capacity of the 
procedure to appreciate small variation in breath composition, in 
consequence of the glucose administration.  
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Analyzing exhaled breath composition during OGT test, we noted 
the presence of two compounds, namely 3-hydroxy butan-2-one 
(acetoin) and butane-2,3-dione (diacetyl), that are absent or at very 
low concentration during fasting state and increase following the 
glucose administration. 
Figures 5.12 and 5.13 show illustrative examples of 3-hydroxy 
butan-2-one and butane-2,3-dione breath concentration values (of 
six subjects) during OGT test. 
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Figure 5.12Breath 3-hydroxy butan-2-one concentrations during OGT test. 
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present inside mouth or gut of the subjects and activated during 
the test. 
 
 
5.3 Kinetic post-operative elimination of sevoflurane 
anaesthetic and hexafluoroisopropanol 
metabolite as measured in exhaled breath 
 
This study was approved by Ethical Committee of Pisa University 
Hospital. Aim of the study was the development of pharmacokinetic 
models relevant to the elimination kinetics of sevoflurane and its 
metabolite hexafluoroisopropanol (HFIP) in the exhaled breath of 
patients undergoing various surgeries. Since sevoflurane 
conversion to HFIP happens in the liver, this would be a first step 
towards investigating the possibility of a non-invasive monitoring of 
the liver function in case of liver transplants. 
Six patients with a supposedly healthy liver undergoing a variety of 
surgeries were recruited at Pisa hospital (Operative Unit of 
Medicine and Surgery, Azienda Ospedaliero Universitaria Pisana). 
Table 5.1 provides a summary of personal and clinical information 
for these patients, including gender, age, height, body weight, body 
mass index, type of surgery, duration of surgery, and total dose of 
anaesthetic. 
The total dose of anaesthetic delivered to the patients was 
estimated by recording the ventilation data and sevoflurane 
input/output concentration values in the endotracheal tube. No 
HFIP measurements could be carried out during surgery. 
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Table 5.1 Summary of personal and clinical information concerning the 
patients. 
Personal data 
ID Genger Age Height (m) Body weight (Kg) 
Body Mass Index 
(Kg/m2) 
1 M 73 1.68 80 28 
2 F 67 1.63 53 20 
3 F 69 1.65 77 28 
4 F 72 1.64 75 28 
5 M 73 1.70 80 28 
6 M 74 1.77 92 29 
Clinical data 
ID Type of surgery Duration of surgery (h) 
Estimated dose of anaesthetic 
(g) 
1 Descending colectomy 3 18.9 
2 Distal pancreatectomy 2.7 19 
3 Adrenalectomy and splenectomy 4.1 10.8 
4 Bowel resection with colostomy 6.3 41.1 
5 Gastrectomy 4.4 34.1 
6 Lower anterior resection 8.7 78.4 
Post-operative breath samples were collected for up to 6 days by 
asking the subjects to inflate Nalophan bags. Collection times were 
the patient’s awakening, the morning and afternoon of the two 
days following surgery, and mornings from the third day on. 
Sample analysis was performed as soon as possible, in any case 
within two hours from sampling. Breath samples were treated as 
described into paragraph 4.1.4 and then thermally desorbed and 
analyzed according to the methods reported in Table 3.2. 
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Post-operative breath concentrations of sevoflurane and HFIP are 
reported in Figures 5.15 and 5.16 respectively. 
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Figure 5.15 Post-operative sevoflurane concentrations in the exhaled 
breath of patients after various surgeries. 
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Figure 5.16 Post-operative HFIP concentrations in the exhaled breath of 
patients after various surgeries. 
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A rapid wash-out of sevoflurane within 24 hours was observed in 
all the patients, whereas the post-operative HFIP concentration 
profiles in breath were more varied. Such variability may be 
associated to the possible genetic heterogeneity of hepatic 
metabolic pathways (uridine diphosphate glucuronosylltransferase 
(UDPGT), cytochrome CYP 2E1) and/or to different  dose of 
anaesthetic (higher doses could simply take longer to be 
eliminated). A fast pulmonary clearance of the anaesthetic is 
mirrored by a slightly slower wash-out of the metabolite.  
A generic classical pharmacokinetic model based on the 
approximated breath data was developed thanks to the 
collaboration with prof. Pleil of the University of North Carolina. 
The method is based on work previously developed by Pleil et al. 
[277] for assessing the environmental exposure to methyl tertiary 
butyl ether (MTBE) and the elimination of the primary metabolite 
tertiary butyl alcohol (TBA). 
The first data set comprised values from Kharasch et al. [278]. 
These subjects were nominally healthy non-smokers, with normal 
indexes for liver and renal function, who underwent elective 
surgeries and were under sevoflurane anaesthesia for 3 hours. 
Empirical data of blood measurements were estimated from graphs 
and discussions in the available literature [278, 279]. They are 
presented in Table 5.2 both in the original units of μM in plasma 
and in converted units of expected concentrations in exhaled 
breath.  
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Table 5.2 Literature values and unit conversion for sevoflurane uptake 
and sevoflurane and HFIP elimination produced from Kharasch 
et al. [278] and Bourdeaux et al. [279]. 
Tim
e 
(hrs) 
Sevoflurane 
blood (μM) 
HFIP total 
blood (μM)  
(Estimated) 
HFIP free 
blood (μM)   
(Approx.) 
Sevofluran
e breath 
(ppmv)   
(Approx.) 
HFIP 
breath 
(ppmv)   
0 0 0 0 0 0 
0.1 400   14892  
1 650 14 2.1 24200 56 
2 700 21 3.15 26062 85 
3 700 29 4.35 26062 117 
4 190 26 3.9 7074 105 
5 120 45 6.75 4468 182 
6 70 33 4.95 2606 133 
7 60 42 6.3 2234 169 
9 43 33 4.95 1601 133 
11 33 34 5.1 1229 137 
12  33 4.95  133 
24  23 3.45  93 
36  17 2.55  69 
48  12 1.8  48 
60  7 1.05  28 
72  5 0.75  20 
For sevoflurane, we used the accepted value 0.65 for blood/breath 
partition coefficient [279] and the near body temperature 
approximation of 24.2 liters/mole of an ideal gas. For HFIP, we 
first converted the total HFIP measurements into the expected free 
HFIP partition (see column 3) that is available for pulmonary 
elimination as discussed by Bourdeaux et al. [279]. The 
blood/breath ratio for HFIP is not available in the literature. We 
estimated a value of 6.0 based on ratios of sevoflurane/HFIP in 
plasma from Kharasch compared to sevoflurane/HFIP ratios in 
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breath observed by us. The resultant calculated breath 
concentrations, expressed as ppmv in air, are given in columns 5 
and 6. We note that these approximations serve only as scaling 
factors and so do not affect the shape of the graphs or the 
subsequent models. 
A second set of empirical data of blood measurements are 
estimated from graphs and discussions from Yasuda et al. [280] 
and are presented in Table 5.3. These data do not include values 
for the metabolite HFIP and so are only useful for validating the 
uptake and elimination kinetics of sevoflurane itself. In these 
experiments, the researchers used seven healthy male volunteers 
(age 23 ± 3 yrs) and administered 1% sevoflurane gas for 30 
minutes. Data are expressed as a ratio of end tidal exhalation and 
administered concentrations; for consistency with Table 5.2, we 
have converted the data into ppmv in the last column of Table 5.3. 
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Table 5.3 Literature values and unit conversion for sevoflurane uptake 
and elimination from Yasuda et al. [280]. 
Time (hrs) Sevoflurane Fa/Fi 
Sevofluran
e Fa/Fa0 Sevoflurane (ppmv)   
0.000 0  0 
0.013 0.46  4600 
0.017 0.55  5500 
0.025 0.64  6400 
0.033 0.68  6800 
0.050 0.72  7200 
0.083 0.75  7500 
0.125 0.78  7800 
0.167 0.79  7900 
0.208 0.8  8000 
0.250 0.81  8100 
0.333 0.82  8200 
0.417 0.835  8350 
0.483 0.84  8400 
0.517  0.4 3360 
0.625  0.1 840 
0.833  0.06 504 
1.167  0.032 269 
1.500  0.02 168 
2.000  0.012 101 
2.500  0.01 84 
24.000  0.007 59 
The model is developed for sevoflurane using three empirical 
compartments: a first “central” compartment (blood), a second 
compartment (HPT - highly perfused tissues), and a third 
compartment (PPT - poorly perfused tissues) (Figure 5.17). The 
metabolite is tracked using one or two compartments as the 
empirical data dictate; the rate constant Ko is in units of 
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CBlood Sev(t+Δt) = CBlood Sev(t) + Δt·(Ca·Ko) – Δt·[(C1+K1+K5)·CBlood Sev(t)] 
+ Δt·[K2·CHPT Sev(t)] (5.1) 
CHPT Sev(t+Δt) =  CHPT Sev(t) + Δt·[K1·CBlood Sev(t) + K4·CPPT Sev(t)] - Δt· 
[(K3+K2)·CHPT Sev(t)] (5.2) 
CPPT Sev(t+Δt) = CPPT Sev(t) + Δt·[K3·CHPT Sev(t) – K4·CPPT Sev(t)] (5.3) 
CBlood HFIP(t+Δt) = CBlood HFIP(t) + Δt·[K5·CBlood Sev(t) + K7·CHPT HFIP(t)] - Δt 
· [(K6+C2) · CBlood HFIP(t)] (5.4) 
CHPT HFIP(t+Δt) = CHPT HFIP(t) + Δt·[K6·CBlood HFIP(t) – K7·CHPT HFIP(t)] (5.5) 
Subsequently, under the assumptions that the breath 
concentrations are proportional (via blood/breath partition 
coefficients) to the blood concentrations, we calculate: 
 CBreath Sev(t) = 0.65 · CBlood Sev(t)  (5.6) 
and  
CBreath HFIP(t) = 6.0 · CBlood HFIP(t)  (5.7) 
where the C(t)’s denote concentrations, the subscripts identify the 
compartments and the compounds, and the Ki’s and Ci’s denote 
time constants as described in the previous section. The equations 
can be quickly implemented using spreadsheet software such as 
Excel (Microsoft, Seattle, WA). The partition estimates are linear 
functions and so any uncertainty is adjusted during the model 
fine-tuning procedure through the adjustment of a single scaling 
parameter. 
Methods for estimating initial parameters 
The incremental equations are quantified using reasonable 
estimates for rate parameters that are then adjusted to fit over the 
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empirical data. Typically, the first step is to estimate the initial 
uptake rate parameter (Ca · Ko) using Eq. 5.1 above. The initial 
conditions are that concentrations throughout the body are zero at 
time = 0 and we rearrange the equation setting CbloodSev(t) and 
CHPTSev(t) to be very close to zero, and solve for an estimate of the 
initial slope: 
Ca·Ko ≈ [CBlood Sev(t+Δt) - CBlood Sev(t)]/Δt  (5.8) 
which can be empirically evaluated using the earliest (uptake) data 
points available. Given this initial estimate for the uptake 
parameter and an empirical estimate for the steady state 
concentration from data observation, we can estimate the initial 
half-life in the first compartment using a re-arrangement of 
equation 1 from above and the understanding that the slope of the 
curve is zero: 
[CBlood Sev(t+Δt) - CBlood Sev(t)]/Δt = 0 = (Ca·Ko) – [C1+K1+K5]·CBlood Sev(t) 
+ [K2·CHPT Sev(t)]  (5.9)  
And therefore: 
(Ca·Ko) = [C1+K1+K5]·CBlood Sev(t) - [K2·CHPT Sev(t)]  (5.10) 
This is further reduced with the assumption that [K1 · CbloodSev(t)] ≈ 
[K2 · CHPTSev(t)] at steady state conditions leaving the 
approximation: 
(C1 + K5) ≈ (Ca·Ko)/CBlood Sev(t=ss)  (5.11) 
where CbloodSev(t=ss) is the steady state concentration and (Ca · Ko) 
has been estimated in Eq. 5.8. 
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Starting with these basic estimates from empirical data, we can 
construct the initial model that can then be further empirically 
refined with trial and error for the second and third compartments 
as well as the metabolite parameters. 
Initial model construction 
The ppmv estimated data from Kharasch et al. (Table 5.2) was used 
to develop the sevoflurane and HFIP incremental models using the 
approach presented in the methods section. The initial estimate for 
sevoflurane uptake (Ca + Ko) was 2482 ppm/min, the steady state 
concentration estimate in exhaled breath is 26,062 ppmv, and the 
initial elimination rate estimate (C1 + K5) is 0.0952 using methods 
explained above. Subsequently, higher compartments were 
empirically fitted and initial estimates modified to account for 
approximations; Figure 5.18 (a) shows data overlaid onto the 
model. The two-compartment HFIP data were subsequently 
modelled by trial and error, and the data vs. model comparison is 
shown in Figure 5.18 (b). 
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Figure 5.18 Empirical breath data from Table 5.2 [278]. 3 hours 
anesthesia of 6 subjects overlaid onto fitted incremental 
models; sevoflurane (a) and HFIP metabolite (b) concentration 
in exhaled breath. Time scales (x-axes) are set to 
accommodate available data. 
We see that both models represent the respective data sets well 
over a long time frame. We note that there is a great deal of 
variability in the HFIP measurements early in the post-anaesthesia 
period and so the model was fitted among these points and may 
not necessarily represent any specific individual. 
Model application: Yasuda data 
To test the assumption that the sevoflurane model (and by 
inference, the HFIP model) are both subject to linear kinetics, we 
apply the existing model from above to the completely independent 
data from Yasuda et al. [280] as shown in Figure 5.19. The only 
adjustment is for the different administered sevoflurane 
concentration (10,000 ppmv) and shorter administration time (30 
min). Here we see that the model slightly under-predicts speed of 
uptake, and also under-predicts speed of elimination, but overall 
shape and levels are consistent with other data. We attribute this 
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apparent higher pulmonary efficiency to the pre-selection of 
healthy young subjects (mean age 23 yrs) and the fact that they did 
not undergo invasive surgery. In contrast, the patients from Table 
5.2 upon which the model was constructed, all had invasive, albeit 
elective surgery and ranged up to 80 yrs. in age. 
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Figure 5.19 Original model based on Table 5.2 data applied to 
sevoflurane data from Table 5.3. 
These models were used to fit our data (Figures 5.20 and 5.21). 
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Figure 5.20 Sevoflurane model and experimental breath data of 6 
subjects undergoing different surgeries. 
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Figure 5.21 Hexafluoroisopropanol model and experimental breath data 
of 6 subjects undergoing different surgeries. 
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The sevoflurane elimination kinetics after surgery were consistent 
in all subjects, whereas the production and elimination of HFIP 
varied to some extent. We developed subject specific parameters for 
HFIP metabolism and interpreted the differences in the context of 
timing and dose of anaesthesia, type of surgery, and specific host 
factors including gender, age and physical parameters. 
Subsequent studies will allow us to evaluate if such differences 
correlate with the clinical state, and in particular with the recovery 
of the liver function in case of liver transplants. 
 
 
5.4 Monitoring of uremic toxins in spent dialysate 
 
According to experts, filtration in dialysis is a mature technology 
which is not expecting large breakthroughs in the next 10-15 
years. Despite of this, patient monitoring during the dialysis and 
the assessment of the dialysis dose are still at their infancy, 
notwithstanding the potential advantages in terms of quality of life 
and extension of the survival duration that tailored treatments 
could achieve. For this reason, the idea of a non-invasive real time 
monitoring of the efficiency of hemodialysis from the analysis of 
spent dialysate is very attractive. Many uremic toxins absorb in the 
UV region and the monitoring of UV absorbance was proposed as a 
possible tool for a non invasive evaluation of the dialysis dose [281, 
282, 283, 284]. However, the relative contribution of the main 
uremic toxins to UV absorption is still not clear. Moreover, 
fluorimetric measurements on spent dialysate samples have never 
been reported in literature. 
Aim of this study was to assess contributions of the main uremic 
toxins to UV absorbance and fluorimetric emission of spent 
dialysate, to estimate correlations among UV absorbance at specific 
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wavelengths and uremic toxin concentrations in dialysate and 
plasma, and to evaluate the possibility to build a model capable of 
predicting concentration values of these toxins in blood using 
spectrophotometric and/or spectrofluorimetric data. 
Twenty-three patients, 16 males and 7 females aged between 41 
and 88 years, were enrolled in this study after signing written 
informed consent. They were treated three times a week by 
standard bicarbonate hemodialyses (duration 210, 240 or 270 
minutes) at the Operative Unit of Nephrology of the Azienda 
Ospedaliero Universitaria Pisana. Twelve patients were treated by a 
low-flux polysulfone membrane (F8, Fresenius, Homburg, KUF = 
1.8 mL/h/mmHg, Surface = 1.8 m2), height patients were treated 
by a high-flux triacetate membrane (N190FH, Nipro, Japan, KUF = 
84.74 mL/h/mmHg, Surface = 1.9 m2), and three patients were 
treated by a high-flux acrylonitrile and sodium methallyl sulfonate 
copolymer membrane (NEPH500, Gambro, Lund, KUF = 65 
mL/h/mmHg, Surface = 2.15 m2). 
Spent dialysate samples were collected 10, 30, 60, 120, 180 and 
240 minutes after the beginning of the hemodialysis treatments. 
Blood samples were also collected before connecting the patient to 
the dialysis machine and 60, 120 and 240 min after the beginning 
of the dialysis session. 
Aliquots of each spent dialysate sample were analyzed both by 
flow-injection and HPLC according to the experimental conditions 
reported in 3.6. Aliquots of each spent dialysate and blood samples 
were also analyzed in the laboratory of the clinic (Clinical chemical 
laboratory of the Azienda Ospedaliero Universitaria Pisana, AOUP) 
to determine the concentration of urea, uric acid, creatinine and 
β2-microglobulin by standard methods. 
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Figure 5.22 Typical UV signals at λabs = 235 nm (a), λabs = 280 nm (b), λabs 
= 292 nm (c) and fluorescence signals at λExc = 220 nm and 
λEm = 340 nm (d) obtained in spent dialysate at various 
sampling times. 
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Figure 5.22 shows illustrative examples of UV and fluorescence 
signals at various sampling times. As expected, a monotonic 
decrease was observed in all signal intensities as dialysis went on 
due to the corresponding decrease of toxin concentrations in spent 
dialysate. The integration of the flow-injection signals relevant to 
spent dialysate samples collected at various times allowed to 
monitor the decay of signal intensity during treatment (Figure 
5.23). 
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Figure 5.23UV absorption at λabs = 235, 280, 292 nm (a) and fluorescence 
emission at λExc = 220 nm and λEm = 340 nm (b) of samples 
collected at different times during a dialysis session. 
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Table 5.4 shows the correlations existing among data obtained with 
high-flux membranes. Similar values were obtained for all pairs of 
variables with low-flux membranes (with the exception of β2-
microglobulin, which cannot diffuse through these membranes). 
Table 5.4 Correlation coefficients among the variables relevant to high-
flux membranes. UV absorption (λabs = 235, 280 and 292 nm) 
and fluorescence emission (λExc = 220 nm, λEm = 340 nm) were 
measured by flow-injection analysis. 
Correlation 
coefficient 
(r) 
UV 
λ=235 
UV 
λ=280 
UV 
λ=292 
Fluo 
λ=340 
CSD 
Urea 
CSD  
Uric acid 
CSD 
Crea 
CSD 
β2M 
UV λ=235 1 0.95 0.96 0.72 0.76 0.85 0.82 0.50 
UV λ=280  1 0.93 0.75 0.75 0.84 0.77 0.51 
UV λ=292   1 0.63 0.65 0.90 0.78 0.43 
Fluo 
λ=340    1 0.73 0.64 0.74 0.67 
CSD Urea     1 0.67 0.86 0.47 
CSD  
Uric acid      1 0.85 0.62 
CSD Crea       1 0.64 
CSD β2M        1 
The UV absorption data obtained at the three different wavelengths 
are highly correlated (correlation coefficients ≥ 0.93). Good 
correlations were also found among fluorescence emission and UV 
absorption data. In this case, the highest value was found between 
fluorescence emission and UV absorption at λabs = 280 nm (r = 
0.75). This result confirms the hypothesis that the fluorescence 
signal is mainly due to amino acids (tryptophan, tyrosine, 
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phenylalanine), peptides and proteins, which have absorption 
bands at 280 nm. 
Our findings also suggest that no additional information is 
obtained when more than one absorption wavelength is considered. 
Good correlations (correlation coefficients ≥ 0.67) also existed 
among the concentrations of the small molecules, i.e. urea, uric 
acid and creatinine, and among these variables and UV absorption 
at different wavelengths (correlation coefficients ≥ 0.65). The 
concentration of β2-microglobulin, a small protein, showed its 
highest correlation coefficient (r = 0.67) with fluorescence emission. 
The correlation coefficients depict a scenario in which photometric 
and fluorimetric signals are likely due to the cumulative 
contribution of many different chemicals, which are all removed 
according to the same kinetics. 
This is particularly true for small molecules. Figure 3.4 
demonstrates that urea has no appreciable absorption in the range 
200 – 600 nm, nevertheless its concentration values had good 
correlation with UV absorption data (correlation coefficients ≥ 
0.65). β2-microglobulin showed a slightly different behaviour when 
compared to the other molecules, but this can be easily explained 
with its different size. Correlations suggested that 
spectrofluorimetric data could be slightly more informative than 
UV absorption regarding its concentration values. 
From the observations above, it appears that photometric and 
fluorimetric measurements of spent dialysate supply 
complementary information and have the potential for non-invasive 
real time monitoring of the efficiency of hemodialysis treatment. 
The highest correlation coefficient (r = 0.90) reported in table 5.4 
was found between the concentration of uric acid and UV 
absorption at λabs = 292 nm. Figure 5.24 shows the complete set of 
these data (23 dialysis sessions, 6 samples per session). Data 
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relevant to patients treated by a low-flux membrane are reported as 
red circles, whereas data of patients treated by a high-flux 
membrane are reported as blue circles. No remarkable differences 
can be observed among patients treated by a low or high-flux 
membranes. 
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Figure 5.24  UV absorption (λabs = 292 nm, flow-injection analysis) versus 
uric acid concentration in spent dialysate samples. 
The high value of this correlation coefficient suggests that uric acid 
may be responsible for an important fraction of UV absorption at 
292 nm. To verify this hypothesis, the percentage contribution of 
each uremic toxin to the overall UV or fluorescence signal was 
estimated according to the following relation: 
%%
sample
i
i A
A
C =           (5.12) 
where Ai is the area of the peak of the ith-compound calculated from 
its concentration value in spent dialysate sample and from its 
calibration curve (Figures 4.13 – 4.15), whereas Asample is the area 
of the peak of the spent dialysate sample analyzed by flow-injection 
(which includes the contributions from all the components). 
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The average (among all patients) percentage contributions to the 
UV signal at different wavelengths of urea, creatinine, uric acid and 
β2-microglobulin are reported in Table 5.5 together with the 
corresponding standard deviations. β2-microglobulin was only 
present in samples collected from patients treated by high-flux 
membranes. Urea, creatinine, uric acid did not contribute to the 
overall fluorescence signal, whereas β2-microglobulin’s 
contribution was 0.2 % ± 0.1. 
Table 5.5 Average percentage contribution (Ci%) of selected uremic toxins 
to the overall UV absorption of spent dialysate samples at 
different wavelengths and corresponding standard deviation 
(±SD). 
 Percentage contribution (Ci %) ± SD  
Uremic toxin UV λ=235 nm UV λ=280 nm UV λ=292 nm 
Urea 0 % 0 % 0 % 
Creatinine 20 % ± 10 3 % ± 2 3 % ± 2 
Uric acid 30 % ± 10 60 % ± 30 80 % ± 20 
β2-microglobulin 0.3 % ± 0.2 0.2 % ± 0.1 0.2 % ± 0.1 
Table 5.5 demonstrates that uric acid provides the most important 
contribution to the UV signal at 292 nm. Such high percentage 
suggests that this compound should be preferred to urea as 
marker of the efficiency of dialysis for small molecules. Since this 
conclusion conflicts with common belief of urea being responsible 
for UV absorption, further tests were carried out on uric acid and 
UV absorption at λ = 292 nm. 
The concentrations of uric acid in samples collected from eight 
patients 10 and 240 minutes after the hemodialysis beginning were 
determined in our laboratory by calibrating the HPLC system and 
by spiking spent dialysate samples with standard working 
solutions (Paragraph 4.4.1). 
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These results were then compared to values obtained at the clinical 
chemical laboratory by biochemical methods (Table 4.13), 
obtaining a good agreement. 
The maximum percentage deviation for all the samples was less 
than 10 % and one-way analysis of variance calculated a 
probability higher than 98% for the three datasets not to be 
significantly different. Such agreement proved that the HPLC 
system was correctly calibrated and indirectly confirmed the 
accuracy of the estimates of the average percentage contribution of 
uric acid to the overall signal. The spiking of uric acid to the spent 
dialysate samples allowed to confirm the identification of its peak 
within the chromatogram. Furthermore, the linearity of the 
calibration curve in dialysate samples and the coincidence of the 
slope value with the corresponding value of the calibration curve in 
standard working solutions allowed to exclude the existence of any 
notable matrix effect. 
Table 5.6 shows the correlation coefficients between urea, 
creatinine, uric acid and β2-microglobulin concentrations in spent 
dialysate samples (CSD) and in plasma samples (CPl) of all patients1. 
Table 5.6 Correlation coefficients between spent dialysate and plasma 
concentrations data.   
Correlation 
coefficient (r) CPl Urea CPl Creatinine  CPl Uric acid  CPl β2M 
CSD Urea  0.93 0.76 0.68 0.27 
CSD Creatinine  0.63 0.92 0.64 0.44 
CSD Uric acid 0.62 0.70 0.92 0.50 
CSD β2M 0.25 0.51 0.43 0.74 
                                                 
1 23 dialysis sessions, 3 samples per session. β2-microglobulin was only evaluated in the 
11 dialysis sessions with high-flux membranes. Its correlation coefficients with other 
variables only refer to such sessions. 
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Strict correlations between plasma and spent dialysate 
concentration data were observed for all toxins but not for β2-
microglobulin, whose correlation coefficient was remarkably lower 
than the other (but still quite high). 
Good correlations also existed between plasma and dialysate 
concentrations of different toxins, with the usual exception of β2-
microglobulin. 
These results once again indicated that all chemicals were removed 
according to the same kinetics, with β2-microglobulin showing a 
slightly different behaviour.  
The good agreement between plasma and dialysate data suggested 
us to compare the pre- to post-dialysis reduction ratio of urea in 
plasma (URR %) to uric acid reduction ratios estimated by flow-
injection and biochemical analysis in spent dialysate and by 
biochemical analysis in plasma. The URR% is an important 
parameter widely used to quantify the effectiveness of the dialysis 
treatment. 
The uric acid reduction ratio (UARR %) was calculated according 
to: 
%%
pre
postpre
UA
UAUA
UARR
−=           (5.13) 
where UApre and UApost are the pre- and post-dialysis uric acid 
concentration levels respectively. The existence of a transient 
phase at the dialysis beginning, due to the time needed to establish 
the proper fluxes of dialysis fluids as well as the physical 
equilibrium across the membrane, suggested us to consider, for 
spent dialysate datasets, the uric acid concentration in the 
samples collected at t = 10 minutes as UApre. 
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The good agreement found among urea and uric acid reduction 
ratios (Table 5.7) proofs that this molecule and spectrophotometric 
methods can be used to assess the effectiveness of treatment. 
Table 5.7 Uric acid reduction ratios in spent dialysate determined by 
flow- injection analysis (A) and by biochemical method (B). Uric 
acid reduction ratios (C) and urea reduction ratios (D) in 
plasma. Comparison between A and B, C, D. 
  Reduction Ratio (RR %) 
ID A B C D 
Percentage 
deviation 
A-B (%) 
Percentage 
deviation 
A-C (%) 
Percentage 
deviation 
A-D (%) 
P1 69 73 73 70 5 5 1 
P2 49 50 71 67 2 31 27 
P3 51 58 57 61 13 11 17 
P4 58 50 67 75 -17 12 22 
P5 53 60 63 56 11 16 5 
P6 66 70 74 74 5 11 10 
P7 85 79 72 63 -8 -19 -35 
P9 74 77 78 81 4 6 10 
P10 74 79 79 78 6 6 5 
P11 73 76 76 74 4 4 1 
P12 56 63 72 71 11 22 21 
P13 72 73 77 79 2 7 9 
P14 77 86 88 82 10 11 6 
P15 74 79 80 78 6 8 5 
P16 66 68 68 62 2 2 -8 
P17 84 88 79 75 5 -6 -12 
P18 73 77 77 76 5 5 3 
P19 69 76 72 66 9 3 -5 
P20 73 76 76 69 5 5 -6 
P21 78 81 64 72 4 -20 -8 
P22 73 75 78 82 3 6 12 
P23 71 77 76 69 7 6 -3 
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In summary, excellent correlations were obtained between UV 
absorption at λabs = 292 nm and uric acid concentration in spent 
dialysate (r = 0.90, Table 5.4), and between uric acid concentration 
in spent dialysate and in plasma (r = 0.92, Table 5.6). 
Furthermore, we showed that uric acid provides the most 
important contribution to the UV absorption at λabs = 292 nm in 
spent dialysate (CUA % = 75 %, Table 5.5). For this reasons, we 
used the complete set of data to build a linear model (Figure 5.25) 
estimating the uric acid concentration in plasma from the UV 
absorption data at λabs = 292 nm: 
UAPl [mg/dL] = 1.57·10-6 UVabs [A.U.] + 0.75 
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Figure 5.25  Uric acid concentrations in plasma versus UV absorption at 
λabs = 292 nm. Data relevant to patients treated by low- and 
high-flux membrane are reported as red and blue circles 
respectively. 
The accuracy of prediction was estimated by “leave-one-out” cross-
validation [285, 286, 287]. As the name suggests, leave-one-out 
cross-validation (LOOCV) involves using a single observation from 
the original sample as the validation data, and the remaining 
observations as the training data. This is repeated such that each 
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observation in the sample is used once as the validation data. This 
is the same as a K-fold cross-validation with K being equal to the 
number of observations in the original sample. Leave-one-out 
cross-validation is usually very expensive from a computational 
point of view because of the large number of times the training 
process is repeated. 
Data from 22 dialysis sessions (3 data per session) were used to 
build the model (calibration set), then the uric acid concentrations 
predicted by the model from UV absorption data were compared to 
the actual data relevant to the remaining session (validation set). 
Such procedure was repeated for each session and an average 
percentage error in prediction of 26 % was calculated.  
This result allows to be optimistic about the possibility of a real 
time non invasive monitoring of dialysis by spectrophotometric 
measurements in spent dialysate. More accurate predictions could 
likely be obtained by models built from single patient’s data. Such 
models could represent a valid tool for clinicians to assess removal 
of uremic toxins and deliver personalized hemodialysis treatments. 
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CONCLUSIONS 
 
Non traditional human fluids have been confirmed as useful 
sources of chemical information when making a diagnosis or 
monitoring a therapy, provided that reliable analytical methods are 
available. 
A clinical study was performed, which involved 50 patients under 
oral anticoagulant therapy with warfarin. Warfarin concentration 
was determined in oral fluid samples using an optimized method 
based on HPLC with fluorimetric detection. The results 
demonstrated the existence of a pH-dependent correlation between 
oral fluid concentrations of warfarin and INR. If confirmed in a 
larger sample of cases, this result could represent a first step 
towards the development of non-invasive “point of care” systems 
for monitoring patients on anticoagulation therapy. Such an 
outcome would improve a patient’s quality of life and increase the 
safety of anticoagulation therapies. 
Chemical analysis of exhaled breath samples, which was performed 
using an optimized method based on thermal desorption gas 
chromatography and mass spectrometry was applied to the non-
invasive monitoring of both endogenous volatile compounds during 
a oral glucose tolerance test, and sevoflurane and its metabolite 
(HFIP) after surgery. For the latter, a three-compartment 
pharmacokinetic model was developed and fitted to the post-
operative sevoflurane and HFIP breath data. The results suggest 
that the elimination kinetics of sevoflurane and HFIP could 
potentially provide useful information on liver function in a non-
invasive way for use in monitoring patients who have had liver 
transplants . 
Conclusions 
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Spent dialysate samples collected at different times during the 
hemodialysis treatment of 23 patients were analyzed by 
spectrophotometric and spectrofluorimetric measurements at 
various wavelengths. A linear model was developed capable of 
predicting uric acid concentrations in blood from the absorbance of 
spent dialysate at 292 nm. This very promising result shows that 
the real time non-invasive monitoring of toxins removal is feasible, 
which would represent a valid tool for clinicians to deliver 
personalized hemodialysis treatments. 
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